<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01915498</url>
  </required_header>
  <id_info>
    <org_study_id>AG-221-C-001</org_study_id>
    <secondary_id>2013-001784-23</secondary_id>
    <nct_id>NCT01915498</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation</brief_title>
  <official_title>A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of Phase 1 Dose Escalation/Part 1 Expansion are:&#xD;
&#xD;
        -  To assess the safety and tolerability of treatment with enasidenib administered&#xD;
           continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle in&#xD;
           participants with advanced hematologic malignancies.&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or&#xD;
           the recommended Phase 2 dose (RP2D) of enasidenib in participants with advanced&#xD;
           hematologic malignancies.&#xD;
&#xD;
      The primary objective of Phase 2 is:&#xD;
&#xD;
      • To assess the efficacy of enasidenib as treatment for participants with relapsed or&#xD;
      refractory (R/R) acute myelogenous leukemia (AML) with an IDH2 mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)</measure>
    <time_frame>From time of first dose up to the end of Cycle 1; 28 days</time_frame>
    <description>Toxicity severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT was defined as:&#xD;
Non-hematologic toxicities: CTCAE ≥ Grade 3 with the exception of ≥ Grade 3 blood bilirubin increases in participants with a uridine diphosphate- glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) mutation. In participants with a UGT1A1 mutation, blood bilirubin increases of &gt; 5× upper limit of normal (ULN) were considered a DLT.&#xD;
Hematologic toxicities: Prolonged myelosuppression, defined as persistence of ≥ Grade 3 neutropenia or thrombocytopenia (by NCI CTCAE v4.03), leukemia-specific criteria, i.e., marrow cellularity &lt;5% on Day 28 or later from the start of study drug without evidence of leukemia) at least 42 days after the initiation of Cycle 1 therapy. Leukemia-specific grading was used for cytopenias (based on percentage decrease from Baseline: 50 to 75% = Grade 3, &gt;75% = Grade 4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff date of 01 September 2017; median treatment duration in the dose escalation phase was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 Dose Expansion: Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From the first dose of investigational product (IP) up to 28 days after the last dose of IP up to the data cutoff date of 01 September 2017; median treatment duration in Part 1 Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>ORR is defined as the percentage of participants achieving an overall response of complete response (CR), CR with incomplete neutrophil recovery (CRi), CR with incomplete platelet recovery (CRp), partial response (PR), or morphologic leukemia-free state (MLFS) based on the 2003 revised International Working Group (IWG) criteria for AML, assessed by the Investigator.&#xD;
CR:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelets &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion: Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff of date of 01 September 2017; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Follow-up: Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From the primary analysis cut-off date of 01 September 2017 to the final analysis cut-off date of 29 July 2019, a maximum of 23 months.</time_frame>
    <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation: Investigator Assessed Overall Response Rate (ORR) by Total Daily Dose</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the dose escalation phase was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, marrow CR (mCR) (for MDS) and MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required&#xD;
mCR:&#xD;
Bone marrow myeloblasts ≤ 5% and decreased by ≥ 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, mCR (for MDS), or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required&#xD;
mCR:&#xD;
Bone marrow myeloblasts ≤ 5% and decreased by ≥ 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Phase 1/2: Investigator Assessed Overall Response Rate in Participants With R/R AML</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure for Phase 1 and 2 R/R AML participants was 5.4 months (range 0.4 to 34.2 months).</time_frame>
    <description>For participants with R/R AML ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation: Complete Response Rate (CRR) by Total Daily Dose</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CR for MDS:&#xD;
Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&#xD;
Peripheral blood:&#xD;
Hemoglobin ≥ 11 g/dL&#xD;
Platelets ≥ 100 × 10⁹/L&#xD;
Neutrophils ≥ 1.0 × 10⁹/L&#xD;
Blasts = 0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Complete Response Rate</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CR for MDS:&#xD;
Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&#xD;
Peripheral blood:&#xD;
Hemoglobin ≥ 11 g/dL&#xD;
Platelets ≥ 100 × 10⁹/L&#xD;
Neutrophils ≥ 1.0 × 10⁹/L&#xD;
Blasts = 0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Complete Response Rate</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation: Rate of Complete Response and Complete Response With Incomplete Hematological Recovery (CR/CRi/CRp) by Total Daily Dose</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp), based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator review.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Rate of Complete Response and Complete Responses With Incomplete Hematological Recovery (CR/CRi/CRp)</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the investigator.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Rate of Complete Response and Complete Responses With Incomplete Hematological Recovery (CR/CRi/CRp)</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp) based on the 2003 revised IWG criteria for AML, assessed by the Investigator.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Response (DOR)</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
    <description>Among participants who had a response of CR, CRi, CRp, PR, mCR, or MLFS based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Duration of Response</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
    <description>For participants with an objective response based on the 2003 revised IWG criteria for AML assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. Participants without relapse, progressive disease or death were censored at the last response assessment date.&#xD;
Relapse (for participants who previously attained CR, Cri, CRp or MLFS): BM blasts ≥ 5%, reappearance of blasts in the blood or development of extramedullary disease.&#xD;
Disease progression (for participants who previously attained PR): development of new extramedullary disease, or&#xD;
For participants with 5% to 67% BM blasts at nadir:&#xD;
a &gt; 50% increase in BM blasts from nadir and that is ≥ 20%.&#xD;
For participants with ≥ 67% BM blasts at nadir:&#xD;
a doubling of the nadir absolute peripheral blood (PB) blast count and the final absolute PB blast count &gt; 10 x 10⁹/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Overall Survival</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
    <description>Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Overall Survival</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
    <description>Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Combined: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline</measure>
    <time_frame>Baseline to the end of treatment; overall median duration of treatment exposure in Phase 1 combined was 5.1 months (range 0.4, 34.2 months).</time_frame>
    <description>Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 28 days before and 28 days after the first dose of treatment for Phase 1.&#xD;
Results are reported for all participants in Phase 1 combined and for the subset of participants with R/R AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Combined: Percentage of Participants Who Achieved 56-Day Platelet Transfusion Independence Post-baseline</measure>
    <time_frame>Baseline to the end of treatment; overall median duration of treatment exposure in Phase 1 combined was 5.1 months (range 0.4, 34.2 months).</time_frame>
    <description>Participants who achieved 56-day post-baseline platelet transfusion independence, i.e. with no platelet transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline platelet transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 28 days before and 28 days after the first dose of treatment for Phase 1.&#xD;
Results are reported for all participants in Phase 1 combined and for the subset of participants with R/R AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline</measure>
    <time_frame>Baseline to the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Percentage of Participants Who Achieved 56-Day Platelet Transfusion Independence Post-baseline</measure>
    <time_frame>Baseline to the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>Participants who achieved 56-day post-baseline platelet transfusion independence, i.e. with no platelet transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline platelet transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival (EFS)</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
    <description>Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurs first. Participants without an EFS event were censored at the date of the last adequate response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
    <description>Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurred first. Participants without an EFS event were censored at the date of the last adequate response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Complete Response (DOCR)</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
    <description>Among participants who had a response of CR based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS assessed by the Investigator, duration of complete response was calculated from the date of the first occurrence of complete response to the date of documented disease relapse, progression or death, whichever occurred earlier. DOCR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Duration of Complete Response</measure>
    <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
    <description>Among participants who had a response of CR based on the 2003 revised IWG criteria for AML assessed by the Investigator, duration of complete response was calculated from the date of the first occurrence of complete response to the date of documented disease relapse, progression or death, whichever occurred earlier. DOCR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation: Time to First Response by Total Daily Dose</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, mCR (for MDS) or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS as assessed by the Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Time to First Response</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, mCR (for MDS) or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS as assessed by the Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Time to First Response</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML as assessed by the Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation: Time to Best Response by Total Daily Dose</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Time to Best Response</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Part 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Time to Best Response</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML per investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation: Time to Complete Response by Total Daily Dose</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the Phase 1 Dose Escalation phase was 5.0 months (range 0.4 to 34.2 months).</time_frame>
    <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Expansion: Time to Complete Response</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Part 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
    <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Dose Expansion: Time to Complete Response</measure>
    <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
    <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML per investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Dose Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for assessment of enasidenib pharmacokinetics (PK).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 72 Hours Postdose (AUC0-72) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 72 hours post-dose (AUC0-72) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Concentration of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time to Maximum Concentration (Tmax) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Apparent Terminal Phase Half-life (t½) of Enasidenib After a Single Oral Dose on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
T1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After Multiple Oral Doses</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After Multiple Oral Doses</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After Multiple Oral Doses</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Concentration (Cmax) of Enasidenib After Multiple Oral Doses</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time to Maximum Concentration (Tmax) of Enasidenib After Multiple Oral Doses</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After Single and Multiple Oral Doses</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of enasidenib was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC 0-24) of Enasidenib After Single and Multiple Oral Doses</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After Single and Multiple Oral Doses</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Maximum Concentration (Cmax) of Enasidenib After Single and Multiple Oral Doses</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Maximum Concentration (Tmax) of Enasidenib After Single and Multiple Oral Doses</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Apparent Terminal Phase Half-life (t1/2) of Enasidenib After Single and Multiple Oral Doses</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to hour 8 post-dose (AUC 0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 72 Hours Postdose (AUC0-72) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 72 hours post-dose (AUC0-72) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Concentration of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time to Maximum Concentration (Tmax) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Apparent Terminal Phase Half-life (t½) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
t1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of AGI-16903 After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Concentration (Cmax) of AGI-16903 After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time to Maximum Concentration (Tmax) of AGI-16903 After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Maximum Concentration (Cmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Apparent Terminal Phase Half-life (t1/2) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Maximum Concentration (Cmax) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Time to Maximum Concentration (Tmax) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Maximum Concentration (Cmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</measure>
    <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Percent Change From Baseline for Area Under the Effect Concentration Time Curve From Time 0 to 10 Hours Postdose (%BAUEC0-10) of 2-hydroxyglutarate (2-HG) on Day -3</measure>
    <time_frame>Screening visit, Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of enasidenib; the LLOQ was 30.0 ng/mL.&#xD;
Area under the effect concentration time curve from time point zero (predose) up to 10 hours postdose (AUEC0-10) was calculated using the linear trapezoid rule. Percent change from Baseline for AUEC0-10 was calculated as (AUEC0-10 minus [Baseline*Tlast]) / (Baseline*Tlast) * 100, where Tlast corresponded to 10 hours and Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Screening visit, Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of enasidenib; the LLOQ was 30.0 ng/mL.&#xD;
Minimum percent change from Baseline response value post-dose over 10 hours was calculated as:&#xD;
(minimum observed concentration post-dose over 10 hours [Rmin] - Baseline) / Baseline * 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time of Minimum Observed Concentration Over 72 Hours Postdose (Tmin) of 2-HG After a Single Oral Dose of Enasidenib on Day -3</measure>
    <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
    <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Percent Change From Baseline for Area Under the Effect Concentration Time Curve From Time 0 to 10 Hours Postdose of 2-HG After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL. Area under the effect concentration time curve from time point zero (predose) up to 10 hours postdose (AUEC0-10) was calculated using the linear trapezoid rule. Percent change from baseline for AUEC0-10 was calculated as:&#xD;
(AUEC0-10 minus [Baseline*Tlast]) / (Baseline*Tlast) * 100, where Tlast corresponded to 10 hours and Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.&#xD;
Minimum percent change from Baseline response value post-dose over 10 hours was calculated as:&#xD;
(minimum observed concentration post-dose over 10 hours [Rmin] - Baseline) / Baseline * 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time of Minimum Observed Concentration Over 10 Hours Postdose (Tmin) of 2-HG After Multiple Oral Doses of Enasidenib</measure>
    <time_frame>Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
    <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>enasidenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enasidenib administered orally. Multiple doses will be administered to determine the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib</intervention_name>
    <description>Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.</description>
    <arm_group_label>enasidenib</arm_group_label>
    <other_name>AG-221</other_name>
    <other_name>IDHIFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be greater than or equal to 18 years of age.&#xD;
&#xD;
          2. Subjects must have an advanced hematologic malignancy including:&#xD;
&#xD;
        Phase 1/ Dose escalation:&#xD;
&#xD;
          1. Diagnosis of acute myelogenous leukemia (AML) according to World Health Organization&#xD;
             (WHO) criteria;&#xD;
&#xD;
               -  Disease refractory or relapsed (defined as the reappearance of &gt; 5% blasts in the&#xD;
                  bone marrow).&#xD;
&#xD;
               -  Untreated AML, greater than or equal to 60 years of age and are not candidates&#xD;
                  for standard therapy due to age, performance status, and/or adverse risk factors,&#xD;
                  according to the treating physician and with approval of the Medical Monitor;&#xD;
&#xD;
          2. Diagnosis of Myelodysplastic syndrome (MDS) according to WHO classification with&#xD;
             refractory anemia with excess blasts (RAEB-1 or RAEB-2), or considered high-risk by&#xD;
             the Revised International Prognostic Scoring System (IPSS-R), that is recurrent or&#xD;
             refractory, or the subject is intolerant to established therapy known to provide&#xD;
             clinical benefit for their condition (i.e., subjects must not be candidates for&#xD;
             regimens known to provide clinical benefit), according to the treating physician and&#xD;
             with approval of the Medical Monitor.&#xD;
&#xD;
             Phase 1/Part 1 Expansion:&#xD;
&#xD;
             Arm 1: Relapsed or refractory AML and age greater than or equal to 60 years or any&#xD;
             subject with AML regardless of age who has relapsed following a bone marrow transplant&#xD;
             (BMT).&#xD;
&#xD;
             Arm 2: Relapsed or refractory AML and age &lt;60 years, excluding subjects with AML who&#xD;
             have relapsed following a BMT.&#xD;
&#xD;
             Arm 3: Untreated AML and age greater than or equal to 60 years that decline standard&#xD;
             of care chemotherapy.&#xD;
&#xD;
             Arm 4: Isocitrate dehydrogenase protein, 2 (IDH2)-mutated advanced hematologic&#xD;
             malignancies not eligible for Arms 1 to 3.&#xD;
&#xD;
             Phase 2:&#xD;
&#xD;
             Diagnosis of AML according to World Health Organization (WHO) criteria and disease&#xD;
             relapsed or refractory as defined by:&#xD;
&#xD;
               -  Subjects who relapse after allogeneic transplantation;&#xD;
&#xD;
               -  Subjects in second or later relapse;&#xD;
&#xD;
               -  Subjects who are refractory to initial induction or re-induction treatment&#xD;
&#xD;
               -  Subjects who relapse within 1 year of initial treatment, excluding patients with&#xD;
                  favorable-risk status according to National Comprehensive Cancer Network (NCCN)&#xD;
                  Guidelines. Favorable-risk cytogenetics: inv(16), t(16;16), t(8;21), t(15;17)&#xD;
&#xD;
          3. Subjects must have documented IDH2 gene-mutated disease:&#xD;
&#xD;
               -  For subjects in the dose escalation phase and Part 1 Expansion, IDH2 mutation may&#xD;
                  be based on local evaluation. (Centralized testing will be performed&#xD;
                  retrospectively.)&#xD;
&#xD;
               -  For subjects in the Phase 2 portion of the trial, central testing of IDH2&#xD;
                  mutation of bone marrow aspirate and peripheral blood, is required during&#xD;
                  screening to confirm eligibility&#xD;
&#xD;
          4. Subjects must be amenable to serial bone marrow sampling, peripheral blood sampling&#xD;
             and urine sampling during the study.&#xD;
&#xD;
               -  The diagnosis and evaluation of AML or MDS will be made by bone marrow aspiration&#xD;
                  and/or biopsy. If an aspirate is unobtainable (i.e., a &quot;dry tap&quot;), the diagnosis&#xD;
                  may be made from the core biopsy.&#xD;
&#xD;
               -  Screening bone marrow aspirate and peripheral blood samples are required of all&#xD;
                  subjects. A bone marrow biopsy must be collected if adequate aspirate is not&#xD;
                  attainable unless:&#xD;
&#xD;
                    -  A bone marrow aspirate and biopsy was performed as part of the standard of&#xD;
                       care within 28 days prior to the start of the study treatment; and&#xD;
&#xD;
                    -  Slides of bone marrow aspirate, biopsy and stained peripheral blood smear&#xD;
                       are available for both local and central pathology reviewers; and&#xD;
&#xD;
                    -  A bone marrow aspirate sample acquired within 28 days prior to the start of&#xD;
                       study treatment has been sent for cytogenetic analysis.&#xD;
&#xD;
          5. Subjects must be able to understand and willing to sign an informed consent. A legally&#xD;
             authorized representative may consent on behalf of a subject who is otherwise unable&#xD;
             to provide informed consent, if acceptable to and approved by the site and/or sites&#xD;
             Institutional Review Board (IRB)/Independent Ethics Committee (IEC).&#xD;
&#xD;
          6. Subjects must have Eastern Cooperative Oncology Group (ECOG) Performance status (PS)&#xD;
             of 0 to 2.&#xD;
&#xD;
          7. Platelet count ≥ 20,000/μL (transfusions to achieve this level are allowed). Subjects&#xD;
             with a baseline platelet count of &lt; 20,000/μL due to underlying malignancy are&#xD;
             eligible with Medical Monitor approval.&#xD;
&#xD;
          8. Subjects must have adequate hepatic function as evidenced by:&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), unless considered due&#xD;
                  to Gilbert's disease, a gene mutation in UGT1A1, or leukemic organ involvement,&#xD;
                  following approval by the Medical Monitor;&#xD;
&#xD;
               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline&#xD;
                  phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic organ&#xD;
                  involvement.&#xD;
&#xD;
          9. Subjects must have adequate renal function as evidenced by:&#xD;
&#xD;
             • Serum creatinine ≤ 2.0 × ULN OR&#xD;
&#xD;
             • Creatinine clearance greater than 40 mL/min based on the Cockroft-Gault glomerular&#xD;
             filtration rate (GFR) estimation: (140 - Age) x (weight in kg) x (0.85 if female)/72 x&#xD;
             serum creatinine&#xD;
&#xD;
         10. Subjects must be recovered from any clinically relevant toxic effects of any prior&#xD;
             surgery, radiotherapy, or other therapy intended for the treatment of cancer.&#xD;
             (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or&#xD;
             residual alopecia, are allowed with approval of the Medical Monitor)&#xD;
&#xD;
         11. Female subjects of child-bearing potential must agree to undergo medically supervised&#xD;
             pregnancy test prior to starting study drug. The first pregnancy test will be&#xD;
             performed at screening (within 7 days prior to first study drug administration), and&#xD;
             on the day of the first study drug administration and confirmed negative prior to&#xD;
             dosing and Day 1 before dosing all subsequent cycles.&#xD;
&#xD;
         12. Female subjects with reproductive potential must have a negative serum pregnancy test&#xD;
             within 7 days prior to the start of therapy. Subjects with reproductive potential are&#xD;
             defined as sexually mature women who have not undergone a hysterectomy, bilateral&#xD;
             oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e.,&#xD;
             who have not menstruated at all) for at least 24 consecutive months (i.e., has had&#xD;
             menses at any time in the preceding 24 consecutive months). Females of reproductive&#xD;
             potential as well as fertile men and their partners who are female of reproductive&#xD;
             potential must agree to abstain from sexual intercourse or to use two highly effective&#xD;
             forms of contraception from the time of giving informed consent, during the study and&#xD;
             for 120 days (females and males) following the last dose of AG-221. A highly effective&#xD;
             form of contraception is defined as hormonal oral contraceptives, injectables,&#xD;
             patches, intrauterine devices, double-barrier method (e.g., synthetic condoms,&#xD;
             diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner&#xD;
             sterilization.&#xD;
&#xD;
         13. Able to adhere to the study visit schedule (ie, clinic visits at the study sites are&#xD;
             mandatory, unless noted otherwise for particular study visits) and other protocol&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days&#xD;
             of the first dose of AG-221, or subjects on immunosuppressive therapy post HSCT at the&#xD;
             time of screening, or with clinically significant graft-versus-host disease (GVHD).&#xD;
             (The use of a stable dose of oral steroids post GVHD and/or topical steroids for&#xD;
             ongoing skin GVHD is permitted with Medical Monitor approval.)&#xD;
&#xD;
          2. Subjects who received systemic anticancer therapy or radiotherapy &lt; 14 days prior to&#xD;
             their first day of study drug administration. (Hydroxyurea is allowed for up to 28&#xD;
             days after the start of AG-221 for the control of peripheral leukemic blasts in&#xD;
             subjects with white blood cell [WBC] counts &gt; 30,000/μL as well as prior to&#xD;
             enrollment).&#xD;
&#xD;
          3. Subjects who received a small molecule investigational agent &lt; 14 days prior to their&#xD;
             first day of study drug administration. In addition, the first dose of AG-221 should&#xD;
             not occur before a period ≥ 5 half-lives of the investigational agent has elapsed.&#xD;
&#xD;
          4. Subjects taking the following sensitive cytochrome P450 (CYP) substrate medications&#xD;
             that have a narrow therapeutic range are excluded from the study unless they can be&#xD;
             transferred to other medications within ≥5 half-lives prior to dosing: paclitaxel&#xD;
             (CYP2C8) warfarin, phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6),&#xD;
             theophylline and tizanidine (CYP1A2).&#xD;
&#xD;
          5. Subjects taking the P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP)&#xD;
             transporter-sensitive substrates digoxin and rosuvastatin should be excluded from the&#xD;
             study unless they can be transferred to other medications within ≥ 5 half-lives prior&#xD;
             to dosing.&#xD;
&#xD;
          6. Subjects for whom potentially curative anticancer therapy is available.&#xD;
&#xD;
          7. Subjects who are pregnant or lactating.&#xD;
&#xD;
          8. Subjects with an active severe infection that required anti-infective therapy or with&#xD;
             an unexplained fever &gt; 38.5°C during screening visits or on their first day of study&#xD;
             drug administration (at the discretion of the Investigator, subjects with tumor fever&#xD;
             may be enrolled).&#xD;
&#xD;
          9. Subjects with known hypersensitivity to any of the components of AG-221.&#xD;
&#xD;
         10. Subjects with New York Heart Association (NYHA) Class III or IV congestive heart&#xD;
             failure or left ventricular ejection fraction (LVEF) &lt; 40% by echocardiogram (ECHO) or&#xD;
             multi-gated acquisition (MUGA) scan within approximately 28 days of Cycle 1, Day 1&#xD;
             (C1D1).&#xD;
&#xD;
         11. Subjects with a history of myocardial infarction within the last 6 months of&#xD;
             screening.&#xD;
&#xD;
         12. Subjects with uncontrolled hypertension (systolic blood pressure [BP] &gt;180 mmHg or&#xD;
             diastolic BP &gt; 100 mmHg) at screening are excluded. Subjects requiring 2 or more&#xD;
             medications to control hypertension are eligible with Medical Monitor approval.&#xD;
&#xD;
         13. Subjects with known unstable or uncontrolled angina pectoris.&#xD;
&#xD;
         14. Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.&#xD;
&#xD;
         15. Subjects with heart-rate corrected QT (QTc) interval ≥ 450 msec or other factors that&#xD;
             increase the risk of QT prolongation or arrhythmic events (e.g., heart failure,&#xD;
             hypokalemia, family history of long QT interval syndrome) at screening.&#xD;
&#xD;
         16. Subjects taking medications that are known to prolong the QT interval unless they can&#xD;
             be transferred to other medications within ≥ 5 half-lives prior to dosing.&#xD;
&#xD;
         17. Subjects with known infection with human immunodeficiency virus (HIV) or active&#xD;
             hepatitis B or C.&#xD;
&#xD;
         18. Subjects with any other medical or psychological condition, deemed by the Investigator&#xD;
             to be likely to interfere with a subject's ability to sign informed consent,&#xD;
             cooperate, or participate in the study.&#xD;
&#xD;
         19. Subjects with known dysphagia, short-gut syndrome, gastroparesis, or other conditions&#xD;
             that limit the ingestion or gastrointestinal absorption of drugs administered orally.&#xD;
&#xD;
         20. Subjects with clinical symptoms suggesting active central nervous system (CNS)&#xD;
             leukemia or known CNS leukemia.&#xD;
&#xD;
         21. Subjects with immediately life-threatening, severe complications of leukemia such as&#xD;
             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated&#xD;
             intravascular coagulation.&#xD;
&#xD;
         22. In the Phase 2 portion of the trial only, subjects who have previously received&#xD;
             treatment with an inhibitor of Isocitrate dehydrogenase ( IDH).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Frattini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University Weill Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center - NYC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Gahanna</city>
        <state>Ohio</state>
        <zip>43230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Drug Development Unit</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-85520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie Department Oncologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital haut leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.</citation>
    <PMID>28588020</PMID>
  </reference>
  <reference>
    <citation>Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, de Botton S; AG221-C-001 Study Investigators. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA Oncol. 2018 Aug 1;4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695.</citation>
    <PMID>29346478</PMID>
  </reference>
  <reference>
    <citation>Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.</citation>
    <PMID>30510081</PMID>
  </reference>
  <reference>
    <citation>Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 Nov;33(11):2575-2584. doi: 10.1038/s41375-019-0472-2. Epub 2019 Apr 9.</citation>
    <PMID>30967620</PMID>
  </reference>
  <reference>
    <citation>Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16.</citation>
    <PMID>30013198</PMID>
  </reference>
  <reference>
    <citation>Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, Wu B, Yen KE, Tallman MS, Papaemmanuil E, Penard-Lacronique V, Thakurta A, Vyas P, Levine RL. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.</citation>
    <PMID>28588019</PMID>
  </reference>
  <reference>
    <citation>Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discov. 2017 May;7(5):494-505. doi: 10.1158/2159-8290.CD-16-1049. Epub 2017 Feb 13.</citation>
    <PMID>28193779</PMID>
  </reference>
  <results_reference>
    <citation>Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5.</citation>
    <PMID>32145771</PMID>
  </results_reference>
  <results_reference>
    <citation>Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27.</citation>
    <PMID>29950729</PMID>
  </results_reference>
  <results_reference>
    <citation>Stein EM. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Future Oncol. 2018 Jan;14(1):23-40. doi: 10.2217/fon-2017-0392. Epub 2017 Sep 18.</citation>
    <PMID>29243965</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <results_first_submitted>July 25, 2020</results_first_submitted>
  <results_first_submitted_qc>October 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2020</results_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>hematologic malignancies</keyword>
  <keyword>IDH2</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase II</keyword>
  <keyword>AG-221</keyword>
  <keyword>relapse AML</keyword>
  <keyword>refractory AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT01915498/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT01915498/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 21 sites in France and the United States. The study includes 3 parts: Phase 1 dose escalation, Phase 1 expansion, and Phase 2 expansion.&#xD;
The primary analysis for efficacy was conducted with a cut-off date of 1 September 2017; safety analyses for ongoing participants continued through 29 July 2019.</recruitment_details>
      <pre_assignment_details>In Phase 1 Dose Escalation participants enrolled into sequential cohorts of increasing doses of enasidenib. After the recommended dose was determined enrollment into Phase 1 Expansion and Phase 2 began. Phase 1 Expansion enrolled participants into 4 non-randomized arms. Phase 2 enrolled participants with relapsed/refractory acute myeloid leukemia.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 Dose Escalation: Enasidenib 30 mg BID</title>
          <description>Participants received enasidenib 30 mg tablets twice a day (BID) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1 Dose Escalation: Enasidenib 50 mg BID</title>
          <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Phase 1 Dose Escalation: Enasidenib 75 mg BID</title>
          <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P4">
          <title>Phase 1 Dose Escalation: Enasidenib 100 mg BID</title>
          <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P5">
          <title>Phase 1 Dose Escalation: Enasidenib 150 mg BID</title>
          <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P6">
          <title>Phase 1 Dose Escalation: Enasidenib 50 mg QD</title>
          <description>Participants received enasidenib 50 mg tablets once a day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P7">
          <title>Phase 1 Dose Escalation: Enasidenib 75 mg QD</title>
          <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P8">
          <title>Phase 1 Dose Escalation: Enasidenib 100 mg QD</title>
          <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P9">
          <title>Phase 1 Dose Escalation: Enasidenib 150 mg QD</title>
          <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P10">
          <title>Phase 1 Dose Escalation: Enasidenib 200 mg QD</title>
          <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P11">
          <title>Phase 1 Dose Escalation: Enasidenib 300 mg QD</title>
          <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P12">
          <title>Phase 1 Dose Escalation: Enasidenib 450 mg QD</title>
          <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P13">
          <title>Phase 1 Dose Escalation: Enasidenib 650 mg QD</title>
          <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P14">
          <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
          <description>Participants ≥ 60 years old with relapsed, refractory (R/R) AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P15">
          <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
          <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P16">
          <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
          <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P17">
          <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
          <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P18">
          <title>Phase 2: Enasidenib 100 mg QD</title>
          <description>Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="P19">
          <title>Safety Follow-Up: Enasidenib</title>
          <description>Participants remaining on treatment as of the 01 September 2017 data cut-off date continued to receive enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Analysis (Sept 2013 - Sept 2017)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="49"/>
                <participants group_id="P15" count="25"/>
                <participants group_id="P16" count="25"/>
                <participants group_id="P17" count="27"/>
                <participants group_id="P18" count="106"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="46"/>
                <participants group_id="P15" count="25"/>
                <participants group_id="P16" count="23"/>
                <participants group_id="P17" count="24"/>
                <participants group_id="P18" count="100"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="16"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="24"/>
                <participants group_id="P15" count="14"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="41"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="16"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bone Marrow Transplant (BMT)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="9"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of Intercurrent Condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Medical Condition</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Safety Follow-up (Sept 2017 to July 2019</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set includes all participants who received at least one dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 Dose Escalation: Enasidenib 30 mg BID</title>
          <description>Participants received enasidenib 30 mg tablets twice a day (BID) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Phase 1 Dose Escalation: Enasidenib 50 mg BID</title>
          <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Phase 1 Dose Escalation: Enasidenib 75 mg BID</title>
          <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B4">
          <title>Phase 1 Dose Escalation: Enasidenib 100 mg BID</title>
          <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B5">
          <title>Phase 1 Dose Escalation: Enasidenib 150 mg BID</title>
          <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B6">
          <title>Phase 1 Dose Escalation: Enasidenib 50 mg QD</title>
          <description>Participants received enasidenib 50 mg tablets once a day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B7">
          <title>Phase 1 Dose Escalation: Enasidenib 75 mg QD</title>
          <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B8">
          <title>Phase 1 Dose Escalation: Enasidenib 100 mg QD</title>
          <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B9">
          <title>Phase 1 Dose Escalation: Enasidenib 150 mg QD</title>
          <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B10">
          <title>Phase 1 Dose Escalation: Enasidenib 200 mg QD</title>
          <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B11">
          <title>Phase 1 Dose Escalation: Enasidenib 300 mg QD</title>
          <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B12">
          <title>Phase 1 Dose Escalation: Enasidenib 450 mg QD</title>
          <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B13">
          <title>Phase 1 Dose Escalation: Enasidenib 650 mg QD</title>
          <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B14">
          <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
          <description>Participants ≥ 60 years old with relapsed or refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B15">
          <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
          <description>Participants &lt; 60 years old with relapsed, refractory AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B16">
          <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
          <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B17">
          <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
          <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B18">
          <title>Phase 2: Enasidenib 100 mg QD</title>
          <description>Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="22"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="14"/>
            <count group_id="B11" value="9"/>
            <count group_id="B12" value="5"/>
            <count group_id="B13" value="7"/>
            <count group_id="B14" value="49"/>
            <count group_id="B15" value="25"/>
            <count group_id="B16" value="25"/>
            <count group_id="B17" value="27"/>
            <count group_id="B18" value="106"/>
            <count group_id="B19" value="345"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="6.37"/>
                    <measurement group_id="B2" value="61.3" spread="8.86"/>
                    <measurement group_id="B3" value="64.7" spread="8.38"/>
                    <measurement group_id="B4" value="67.6" spread="12.88"/>
                    <measurement group_id="B5" value="73.6" spread="7.23"/>
                    <measurement group_id="B6" value="71.8" spread="9.00"/>
                    <measurement group_id="B7" value="62.3" spread="13.77"/>
                    <measurement group_id="B8" value="63.9" spread="15.06"/>
                    <measurement group_id="B9" value="73.8" spread="2.48"/>
                    <measurement group_id="B10" value="67.5" spread="14.69"/>
                    <measurement group_id="B11" value="68.3" spread="6.20"/>
                    <measurement group_id="B12" value="70.0" spread="8.77"/>
                    <measurement group_id="B13" value="70.1" spread="5.34"/>
                    <measurement group_id="B14" value="70.5" spread="11.09"/>
                    <measurement group_id="B15" value="49.2" spread="8.12"/>
                    <measurement group_id="B16" value="76.4" spread="6.87"/>
                    <measurement group_id="B17" value="68.1" spread="13.96"/>
                    <measurement group_id="B18" value="66.5" spread="11.88"/>
                    <measurement group_id="B19" value="66.8" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 65 Years Old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="11"/>
                    <measurement group_id="B15" value="25"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="35"/>
                    <measurement group_id="B19" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65- &lt; 75 Years Old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="22"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="13"/>
                    <measurement group_id="B18" value="45"/>
                    <measurement group_id="B19" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 75 Years Old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="16"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="16"/>
                    <measurement group_id="B17" value="10"/>
                    <measurement group_id="B18" value="26"/>
                    <measurement group_id="B19" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="27"/>
                    <measurement group_id="B15" value="12"/>
                    <measurement group_id="B16" value="9"/>
                    <measurement group_id="B17" value="10"/>
                    <measurement group_id="B18" value="42"/>
                    <measurement group_id="B19" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="22"/>
                    <measurement group_id="B15" value="13"/>
                    <measurement group_id="B16" value="16"/>
                    <measurement group_id="B17" value="17"/>
                    <measurement group_id="B18" value="64"/>
                    <measurement group_id="B19" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="8"/>
                    <measurement group_id="B19" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="36"/>
                    <measurement group_id="B15" value="16"/>
                    <measurement group_id="B16" value="22"/>
                    <measurement group_id="B17" value="19"/>
                    <measurement group_id="B18" value="60"/>
                    <measurement group_id="B19" value="234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="7"/>
                    <measurement group_id="B18" value="38"/>
                    <measurement group_id="B19" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="40"/>
                    <measurement group_id="B15" value="17"/>
                    <measurement group_id="B16" value="24"/>
                    <measurement group_id="B17" value="19"/>
                    <measurement group_id="B18" value="78"/>
                    <measurement group_id="B19" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="6"/>
                    <measurement group_id="B19" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Provided</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="21"/>
                    <measurement group_id="B19" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>ECOG performance status is used to describe a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). The scale ranges from 0 to 5: -0 = Fully active, no restrictions; -1 = Restricted activity but ambulatory, able to carry out work of a light nature; -2 = Ambulatory and capable of all self-care but unable to carry out work activities; -3 = Limited self-care, confined to bed or chair more than 50% of waking hours; -4 = Completely disabled, no self-care, confined to bed or chair; -5 = Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 - Fully active</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="10"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="24"/>
                    <measurement group_id="B19" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 - Restricted but ambulatory</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="28"/>
                    <measurement group_id="B15" value="18"/>
                    <measurement group_id="B16" value="13"/>
                    <measurement group_id="B17" value="16"/>
                    <measurement group_id="B18" value="65"/>
                    <measurement group_id="B19" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 - Ambulatory but unable to work</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="11"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="16"/>
                    <measurement group_id="B19" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 - Limited self-care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 - Completely Disabled</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Isocitrate dehydrogenase 2 (IDH2) Mutation Type</title>
          <description>Isocitrate dehydrogenase 2 (IDH2) gene mutations have been described in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Mutations in IDH2 most commonly lead to alterations affecting arginine-172 (R172) or arginine-140 (R140) in IDH2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>R140</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="37"/>
                    <measurement group_id="B15" value="18"/>
                    <measurement group_id="B16" value="17"/>
                    <measurement group_id="B17" value="21"/>
                    <measurement group_id="B18" value="80"/>
                    <measurement group_id="B19" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>R172</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="12"/>
                    <measurement group_id="B15" value="7"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="26"/>
                    <measurement group_id="B19" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uridine Diphosphate-Glucuronosyltransferase 1 Family, Polypeptide A1 (UGT1A1) Mutation Status</title>
          <description>The UGT1A1 gene produces a protein, called the bilirubin uridine diphosphate glucuronosyl transferase (bilirubin-UGT) enzyme, an enzyme that glucuronidates bilirubin, a substance produced when red blood cells are broken down. This enzyme converts the toxic form of bilirubin (unconjugated bilirubin) to its nontoxic form (conjugated bilirubin), making it able to be dissolved and removed from the body. Enasidenib is an inhibitor of UGT1A1.&#xD;
Screening for UGT1A1 mutation was added in Protocol Amendment 4 therefore data are not not available for participants enrolled prior to Amendment 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Heterozygous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="20"/>
                    <measurement group_id="B19" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Homozygous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="10"/>
                    <measurement group_id="B19" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wild Type</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="20"/>
                    <measurement group_id="B19" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="14"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="47"/>
                    <measurement group_id="B15" value="24"/>
                    <measurement group_id="B16" value="21"/>
                    <measurement group_id="B17" value="23"/>
                    <measurement group_id="B18" value="36"/>
                    <measurement group_id="B19" value="258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="20"/>
                    <measurement group_id="B19" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytogenetic Risk Status</title>
          <description>Cytogenetic risk classification according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia. Risk categories are based on analysis of cytogenetics (the study of chromosomes), including chromosomal deletions, duplications, or substitutions and analysis of molecular abnormalities such as specific mutations. Better risk indicates disease more likely to respond to initial treatment and less likely to relapse whereas poor-risk is characterized by poor response to induction chemotherapy and higher relapse rates.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Favorable-Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermediate-Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="19"/>
                    <measurement group_id="B15" value="14"/>
                    <measurement group_id="B16" value="13"/>
                    <measurement group_id="B17" value="19"/>
                    <measurement group_id="B18" value="57"/>
                    <measurement group_id="B19" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor-Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="26"/>
                    <measurement group_id="B19" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="6"/>
                    <measurement group_id="B19" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="15"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="17"/>
                    <measurement group_id="B19" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Marrow Blasts</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 20% Blasts</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="11"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="16"/>
                    <measurement group_id="B18" value="22"/>
                    <measurement group_id="B19" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20% to &lt; 30% Blasts</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="14"/>
                    <measurement group_id="B19" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30% to &lt; 50% Blasts</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="18"/>
                    <measurement group_id="B19" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50% Blasts</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="26"/>
                    <measurement group_id="B15" value="12"/>
                    <measurement group_id="B16" value="10"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="49"/>
                    <measurement group_id="B19" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Malignancy Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="106"/>
                    <count group_id="B19" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Relapsed / Refractory Acute Myeloid Leukemia (AML)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="48"/>
                    <measurement group_id="B15" value="25"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="9"/>
                    <measurement group_id="B18" value="105"/>
                    <measurement group_id="B19" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Untreated AML</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="22"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myelodysplastic Syndrome (MDS)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="7"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <population>Participants with available data.</population>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="105"/>
                    <count group_id="B19" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.0" lower_limit="72.0" upper_limit="95.0"/>
                    <measurement group_id="B2" value="97.0" lower_limit="82.0" upper_limit="138.0"/>
                    <measurement group_id="B3" value="86.0" lower_limit="76.0" upper_limit="111.0"/>
                    <measurement group_id="B4" value="97.5" lower_limit="75.0" upper_limit="109.0"/>
                    <measurement group_id="B5" value="91.0" lower_limit="75.0" upper_limit="93.0"/>
                    <measurement group_id="B6" value="89.0" lower_limit="77.0" upper_limit="102.0"/>
                    <measurement group_id="B7" value="92.0" lower_limit="73.0" upper_limit="110.0"/>
                    <measurement group_id="B8" value="96.5" lower_limit="78.0" upper_limit="124.0"/>
                    <measurement group_id="B9" value="94.0" lower_limit="79.0" upper_limit="132.0"/>
                    <measurement group_id="B10" value="87.5" lower_limit="76.0" upper_limit="125.0"/>
                    <measurement group_id="B11" value="93.0" lower_limit="78.0" upper_limit="131.0"/>
                    <measurement group_id="B12" value="103.0" lower_limit="70.0" upper_limit="121.0"/>
                    <measurement group_id="B13" value="95.0" lower_limit="76.0" upper_limit="122.0"/>
                    <measurement group_id="B14" value="93.0" lower_limit="69.0" upper_limit="125.0"/>
                    <measurement group_id="B15" value="93.0" lower_limit="70.0" upper_limit="129.0"/>
                    <measurement group_id="B16" value="89.0" lower_limit="70.0" upper_limit="111.0"/>
                    <measurement group_id="B17" value="92.0" lower_limit="71.0" upper_limit="152.0"/>
                    <measurement group_id="B18" value="89.0" lower_limit="70.0" upper_limit="156.0"/>
                    <measurement group_id="B19" value="90.0" lower_limit="69.0" upper_limit="156.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelets</title>
          <population>Participants with available data</population>
          <units>10^9 cells/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="105"/>
                    <count group_id="B19" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" lower_limit="15.0" upper_limit="147.0"/>
                    <measurement group_id="B2" value="91.0" lower_limit="13.0" upper_limit="158.0"/>
                    <measurement group_id="B3" value="102.0" lower_limit="17.0" upper_limit="167.0"/>
                    <measurement group_id="B4" value="92.0" lower_limit="14.0" upper_limit="507.0"/>
                    <measurement group_id="B5" value="44.0" lower_limit="26.0" upper_limit="183.0"/>
                    <measurement group_id="B6" value="23.0" lower_limit="12.0" upper_limit="287.0"/>
                    <measurement group_id="B7" value="52.0" lower_limit="8.0" upper_limit="253.0"/>
                    <measurement group_id="B8" value="35.5" lower_limit="5.0" upper_limit="194.0"/>
                    <measurement group_id="B9" value="48.0" lower_limit="12.0" upper_limit="72.0"/>
                    <measurement group_id="B10" value="42.0" lower_limit="9.0" upper_limit="282.0"/>
                    <measurement group_id="B11" value="63.0" lower_limit="21.0" upper_limit="486.0"/>
                    <measurement group_id="B12" value="73.0" lower_limit="29.0" upper_limit="170.0"/>
                    <measurement group_id="B13" value="45.9" lower_limit="17.0" upper_limit="247.0"/>
                    <measurement group_id="B14" value="39.0" lower_limit="1.0" upper_limit="197.0"/>
                    <measurement group_id="B15" value="37.0" lower_limit="6.0" upper_limit="292.0"/>
                    <measurement group_id="B16" value="58.0" lower_limit="12.0" upper_limit="529.0"/>
                    <measurement group_id="B17" value="57.0" lower_limit="13.0" upper_limit="644.0"/>
                    <measurement group_id="B18" value="36.0" lower_limit="2.0" upper_limit="1288.0"/>
                    <measurement group_id="B19" value="42.9" lower_limit="1.0" upper_limit="1228.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Absolute Neutrophil Count (ANC)</title>
          <population>Participants with available data</population>
          <units>10^9 cells/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="23"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="105"/>
                    <count group_id="B19" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" lower_limit="0.0" upper_limit="12.6"/>
                    <measurement group_id="B2" value="1.1" lower_limit="0.4" upper_limit="4.7"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0.0" upper_limit="15.5"/>
                    <measurement group_id="B4" value="0.3" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="B5" value="0.5" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="B6" value="0.2" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="B7" value="0.2" lower_limit="0.0" upper_limit="1.4"/>
                    <measurement group_id="B8" value="0.5" lower_limit="0.0" upper_limit="32.1"/>
                    <measurement group_id="B9" value="1.0" lower_limit="0.1" upper_limit="2.5"/>
                    <measurement group_id="B10" value="0.4" lower_limit="0.1" upper_limit="7.4"/>
                    <measurement group_id="B11" value="0.6" lower_limit="0.1" upper_limit="11.0"/>
                    <measurement group_id="B12" value="0.1" lower_limit="0.1" upper_limit="1.1"/>
                    <measurement group_id="B13" value="0.8" lower_limit="0.1" upper_limit="3.4"/>
                    <measurement group_id="B14" value="0.4" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="B15" value="0.1" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="B16" value="0.4" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="B17" value="1.0" lower_limit="0.1" upper_limit="11.7"/>
                    <measurement group_id="B18" value="0.3" lower_limit="0.0" upper_limit="70.0"/>
                    <measurement group_id="B19" value="0.4" lower_limit="0.0" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White Blood Cell Count</title>
          <population>Participants with available data</population>
          <units>10^9 cells/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="9"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="22"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="14"/>
                    <count group_id="B11" value="9"/>
                    <count group_id="B12" value="5"/>
                    <count group_id="B13" value="7"/>
                    <count group_id="B14" value="49"/>
                    <count group_id="B15" value="25"/>
                    <count group_id="B16" value="25"/>
                    <count group_id="B17" value="27"/>
                    <count group_id="B18" value="105"/>
                    <count group_id="B19" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="0.6" upper_limit="57.2"/>
                    <measurement group_id="B2" value="2.1" lower_limit="0.3" upper_limit="31.3"/>
                    <measurement group_id="B3" value="2.0" lower_limit="0.2" upper_limit="39.7"/>
                    <measurement group_id="B4" value="2.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="B5" value="1.9" lower_limit="1.5" upper_limit="16.8"/>
                    <measurement group_id="B6" value="2.6" lower_limit="0.5" upper_limit="20.2"/>
                    <measurement group_id="B7" value="2.1" lower_limit="0.5" upper_limit="14.7"/>
                    <measurement group_id="B8" value="5.3" lower_limit="0.6" upper_limit="88.2"/>
                    <measurement group_id="B9" value="3.3" lower_limit="0.8" upper_limit="26.9"/>
                    <measurement group_id="B10" value="2.6" lower_limit="0.5" upper_limit="34.5"/>
                    <measurement group_id="B11" value="2.4" lower_limit="0.7" upper_limit="47.9"/>
                    <measurement group_id="B12" value="1.3" lower_limit="0.7" upper_limit="17.0"/>
                    <measurement group_id="B13" value="3.6" lower_limit="0.8" upper_limit="38.3"/>
                    <measurement group_id="B14" value="3.0" lower_limit="0.2" upper_limit="64.5"/>
                    <measurement group_id="B15" value="3.1" lower_limit="0.4" upper_limit="26.9"/>
                    <measurement group_id="B16" value="2.3" lower_limit="0.3" upper_limit="25.7"/>
                    <measurement group_id="B17" value="2.7" lower_limit="0.4" upper_limit="26.7"/>
                    <measurement group_id="B18" value="2.0" lower_limit="0.2" upper_limit="93.8"/>
                    <measurement group_id="B19" value="2.4" lower_limit="0.2" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)</title>
        <description>Toxicity severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT was defined as:&#xD;
Non-hematologic toxicities: CTCAE ≥ Grade 3 with the exception of ≥ Grade 3 blood bilirubin increases in participants with a uridine diphosphate- glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) mutation. In participants with a UGT1A1 mutation, blood bilirubin increases of &gt; 5× upper limit of normal (ULN) were considered a DLT.&#xD;
Hematologic toxicities: Prolonged myelosuppression, defined as persistence of ≥ Grade 3 neutropenia or thrombocytopenia (by NCI CTCAE v4.03), leukemia-specific criteria, i.e., marrow cellularity &lt;5% on Day 28 or later from the start of study drug without evidence of leukemia) at least 42 days after the initiation of Cycle 1 therapy. Leukemia-specific grading was used for cytopenias (based on percentage decrease from Baseline: 50 to 75% = Grade 3, &gt;75% = Grade 4)</description>
        <time_frame>From time of first dose up to the end of Cycle 1; 28 days</time_frame>
        <population>All participants who took at least one dose of study drug in the dose escalation phase and either had a DLT during Cycle 1, regardless of the amount of study drug exposure, or had no DLT and completed at least 75% of their planned Cycle 1 doses, and were considered to have had enough safety data to conclude that a DLT did not occur during Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)</title>
          <description>Toxicity severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT was defined as:&#xD;
Non-hematologic toxicities: CTCAE ≥ Grade 3 with the exception of ≥ Grade 3 blood bilirubin increases in participants with a uridine diphosphate- glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) mutation. In participants with a UGT1A1 mutation, blood bilirubin increases of &gt; 5× upper limit of normal (ULN) were considered a DLT.&#xD;
Hematologic toxicities: Prolonged myelosuppression, defined as persistence of ≥ Grade 3 neutropenia or thrombocytopenia (by NCI CTCAE v4.03), leukemia-specific criteria, i.e., marrow cellularity &lt;5% on Day 28 or later from the start of study drug without evidence of leukemia) at least 42 days after the initiation of Cycle 1 therapy. Leukemia-specific grading was used for cytopenias (based on percentage decrease from Baseline: 50 to 75% = Grade 3, &gt;75% = Grade 4)</description>
          <population>All participants who took at least one dose of study drug in the dose escalation phase and either had a DLT during Cycle 1, regardless of the amount of study drug exposure, or had no DLT and completed at least 75% of their planned Cycle 1 doses, and were considered to have had enough safety data to conclude that a DLT did not occur during Cycle 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
        <time_frame>From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff date of 01 September 2017; median treatment duration in the dose escalation phase was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>The safety analysis set includes all participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
          <population>The safety analysis set includes all participants who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="14"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="9"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to Investigational Product (IP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Discontinuation (D/C) of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to D/C of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1 Dose Expansion: Number of Participants With Treatment Emergent Adverse Events</title>
        <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
        <time_frame>From the first dose of investigational product (IP) up to 28 days after the last dose of IP up to the data cutoff date of 01 September 2017; median treatment duration in Part 1 Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>All participants in Phase 1 Expansion who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed or refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with relapsed, refractory AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Number of Participants With Treatment Emergent Adverse Events</title>
          <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
          <population>All participants in Phase 1 Expansion who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Treatment-emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to Investigational Product (IP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Discontinuation (D/C) of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to D/C of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to IP Interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of participants achieving an overall response of complete response (CR), CR with incomplete neutrophil recovery (CRi), CR with incomplete platelet recovery (CRp), partial response (PR), or morphologic leukemia-free state (MLFS) based on the 2003 revised International Working Group (IWG) criteria for AML, assessed by the Investigator.&#xD;
CR:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelets &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of participants achieving an overall response of complete response (CR), CR with incomplete neutrophil recovery (CRi), CR with incomplete platelet recovery (CRp), partial response (PR), or morphologic leukemia-free state (MLFS) based on the 2003 revised International Working Group (IWG) criteria for AML, assessed by the Investigator.&#xD;
CR:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelets &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="27.9" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2 Dose Expansion: Number of Participants With Treatment Emergent Adverse Events</title>
        <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
        <time_frame>From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff of date of 01 September 2017; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Number of Participants With Treatment Emergent Adverse Events</title>
          <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Treatment-emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to Investigational Product (IP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Discontinuation (D/C) of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to D/C of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Follow-up: Number of Participants With Treatment Emergent Adverse Events</title>
        <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
        <time_frame>From the primary analysis cut-off date of 01 September 2017 to the final analysis cut-off date of 29 July 2019, a maximum of 23 months.</time_frame>
        <population>Participants who received at least 1 dose of study treatment during the Safety Follow-up Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Follow-up: Enasidenib</title>
            <description>Participants remaining on treatment as of the 01 September 2017 data cut-off date continued to receive enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Follow-up: Number of Participants With Treatment Emergent Adverse Events</title>
          <description>A TEAE is any adverse event that began or worsened on or after the start of investigational product (IP) through 28 days after the last dose. A treatment-related TEAE is a TEAE that is suspected (possibly or probably related) by the Investigator to be related to the IP. A serious AE is one that at any dose of IP or at any time during the observation period met the following criteria:&#xD;
Resulted in death;&#xD;
Was life threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Was medically important.&#xD;
The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 4.03, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).</description>
          <population>Participants who received at least 1 dose of study treatment during the Safety Follow-up Period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to Investigational Product (IP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE Related to IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Discontinuation (D/C) of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to D/C of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Reduction of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Related to IP Leading to Interruption of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation: Investigator Assessed Overall Response Rate (ORR) by Total Daily Dose</title>
        <description>ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, marrow CR (mCR) (for MDS) and MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required&#xD;
mCR:&#xD;
Bone marrow myeloblasts ≤ 5% and decreased by ≥ 50%</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the dose escalation phase was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg</title>
            <description>Participants received enasidenib 50 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 60 mg</title>
            <description>Participants who received a total daily dose of enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg</title>
            <description>Participants who received a total daily dose of enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg</title>
            <description>Participants who received a total daily dose of enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg</title>
            <description>Participants who received a total daily dose of enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg</title>
            <description>Participants who received a total daily dose of enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg</title>
            <description>Participants who received a total daily dose of enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg</title>
            <description>Participants who received a total daily dose of enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg</title>
            <description>Participants who received a total daily dose of enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Investigator Assessed Overall Response Rate (ORR) by Total Daily Dose</title>
          <description>ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, marrow CR (mCR) (for MDS) and MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required&#xD;
mCR:&#xD;
Bone marrow myeloblasts ≤ 5% and decreased by ≥ 50%</description>
          <population>All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                    <measurement group_id="O2" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O3" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O4" value="44.8" lower_limit="26.4" upper_limit="64.3"/>
                    <measurement group_id="O5" value="46.2" lower_limit="19.2" upper_limit="74.9"/>
                    <measurement group_id="O6" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O7" value="35.7" lower_limit="12.8" upper_limit="64.9"/>
                    <measurement group_id="O8" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O9" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, mCR (for MDS), or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required&#xD;
mCR:&#xD;
Bone marrow myeloblasts ≤ 5% and decreased by ≥ 50%</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>All participants who received at least one dose of study treatment in Phase 1 Expansion.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, mCR (for MDS), or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required&#xD;
mCR:&#xD;
Bone marrow myeloblasts ≤ 5% and decreased by ≥ 50%</description>
          <population>All participants who received at least one dose of study treatment in Phase 1 Expansion.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="32.5" upper_limit="61.7"/>
                    <measurement group_id="O2" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                    <measurement group_id="O3" value="36.0" lower_limit="18.0" upper_limit="57.5"/>
                    <measurement group_id="O4" value="44.4" lower_limit="25.5" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Phase 1/2: Investigator Assessed Overall Response Rate in Participants With R/R AML</title>
        <description>For participants with R/R AML ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure for Phase 1 and 2 R/R AML participants was 5.4 months (range 0.4 to 34.2 months).</time_frame>
        <population>All participants in Phase 1 and 2 with R/R AML who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 or 2 with relapsed or refractory (R/R) AML who received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Phase 1/2: Investigator Assessed Overall Response Rate in Participants With R/R AML</title>
          <description>For participants with R/R AML ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)&#xD;
PR:&#xD;
Meets hematologic criteria of CR&#xD;
Decrease of BM blasts to 5-25% and decrease of pretreatment BM blast ≥ 50%.&#xD;
MLFS:&#xD;
Bone marrow blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Absence of extramedullary disease&#xD;
No hematologic recovery required</description>
          <population>All participants in Phase 1 and 2 with R/R AML who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" lower_limit="32.2" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation: Complete Response Rate (CRR) by Total Daily Dose</title>
        <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CR for MDS:&#xD;
Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&#xD;
Peripheral blood:&#xD;
Hemoglobin ≥ 11 g/dL&#xD;
Platelets ≥ 100 × 10⁹/L&#xD;
Neutrophils ≥ 1.0 × 10⁹/L&#xD;
Blasts = 0%</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 60 mg</title>
            <description>Participants who received a total daily dose of enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg</title>
            <description>Participants who received a total daily dose of enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg</title>
            <description>Participants who received a total daily dose of enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg</title>
            <description>Participants who received a total daily dose of enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg</title>
            <description>Participants who received a total daily dose of enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg</title>
            <description>Participants who received a total daily dose of enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg</title>
            <description>Participants who received a total daily dose of enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg</title>
            <description>Participants who received a total daily dose of enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Complete Response Rate (CRR) by Total Daily Dose</title>
          <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CR for MDS:&#xD;
Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&#xD;
Peripheral blood:&#xD;
Hemoglobin ≥ 11 g/dL&#xD;
Platelets ≥ 100 × 10⁹/L&#xD;
Neutrophils ≥ 1.0 × 10⁹/L&#xD;
Blasts = 0%</description>
          <population>All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.8" upper_limit="60.0"/>
                    <measurement group_id="O2" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O4" value="27.6" lower_limit="12.7" upper_limit="47.2"/>
                    <measurement group_id="O5" value="15.4" lower_limit="1.9" upper_limit="45.4"/>
                    <measurement group_id="O6" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O7" value="21.4" lower_limit="4.7" upper_limit="50.8"/>
                    <measurement group_id="O8" value="40.0" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O9" value="28.6" lower_limit="3.7" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Complete Response Rate</title>
        <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CR for MDS:&#xD;
Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&#xD;
Peripheral blood:&#xD;
Hemoglobin ≥ 11 g/dL&#xD;
Platelets ≥ 100 × 10⁹/L&#xD;
Neutrophils ≥ 1.0 × 10⁹/L&#xD;
Blasts = 0%</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>All participants in Phase 1 Dose Expansion who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Complete Response Rate</title>
          <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CR for MDS:&#xD;
Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&#xD;
Peripheral blood:&#xD;
Hemoglobin ≥ 11 g/dL&#xD;
Platelets ≥ 100 × 10⁹/L&#xD;
Neutrophils ≥ 1.0 × 10⁹/L&#xD;
Blasts = 0%</description>
          <population>All participants in Phase 1 Dose Expansion who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="11.8" upper_limit="36.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.7"/>
                    <measurement group_id="O3" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                    <measurement group_id="O4" value="22.2" lower_limit="8.6" upper_limit="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Complete Response Rate</title>
        <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Complete Response Rate</title>
          <description>Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML as assessed by the investigator.&#xD;
CR for AML:&#xD;
Absolute neutrophil count (ANC) &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="12.8" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation: Rate of Complete Response and Complete Response With Incomplete Hematological Recovery (CR/CRi/CRp) by Total Daily Dose</title>
        <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp), based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator review.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 60 mg</title>
            <description>Participants who received a total daily dose of enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg</title>
            <description>Participants who received a total daily dose of enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg</title>
            <description>Participants who received a total daily dose of enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg</title>
            <description>Participants who received a total daily dose of enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg</title>
            <description>Participants who received a total daily dose of enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg</title>
            <description>Participants who received a total daily dose of enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg</title>
            <description>Participants who received a total daily dose of enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg</title>
            <description>Participants who received a total daily dose of enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Rate of Complete Response and Complete Response With Incomplete Hematological Recovery (CR/CRi/CRp) by Total Daily Dose</title>
          <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp), based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator review.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
          <population>All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.8" upper_limit="60.0"/>
                    <measurement group_id="O2" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O4" value="31.0" lower_limit="15.3" upper_limit="50.8"/>
                    <measurement group_id="O5" value="15.4" lower_limit="1.9" upper_limit="45.4"/>
                    <measurement group_id="O6" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O7" value="28.6" lower_limit="8.4" upper_limit="58.1"/>
                    <measurement group_id="O8" value="40.0" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O9" value="57.1" lower_limit="18.4" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Rate of Complete Response and Complete Responses With Incomplete Hematological Recovery (CR/CRi/CRp)</title>
        <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the investigator.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>All participants who received at least one dose of study treatment in Phase 1 Dose Expansion.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Rate of Complete Response and Complete Responses With Incomplete Hematological Recovery (CR/CRi/CRp)</title>
          <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the investigator.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
          <population>All participants who received at least one dose of study treatment in Phase 1 Dose Expansion.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="16.6" upper_limit="43.3"/>
                    <measurement group_id="O2" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="24.0" lower_limit="9.4" upper_limit="45.1"/>
                    <measurement group_id="O4" value="25.9" lower_limit="11.1" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Rate of Complete Response and Complete Responses With Incomplete Hematological Recovery (CR/CRi/CRp)</title>
        <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp) based on the 2003 revised IWG criteria for AML, assessed by the Investigator.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Rate of Complete Response and Complete Responses With Incomplete Hematological Recovery (CR/CRi/CRp)</title>
          <description>The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp) based on the 2003 revised IWG criteria for AML, assessed by the Investigator.&#xD;
CR:&#xD;
ANC &gt; 1.0 x10⁹/L&#xD;
Platelet count &gt; 100 x10⁹/L&#xD;
Bone marrow (BM) blasts &lt; 5%&#xD;
Absence of blasts with Auer rods&#xD;
Independence of red cell transfusions&#xD;
CRi:&#xD;
All CR criteria except for residual neutropenia (ANC &lt; 1.0 x 10⁹/L&#xD;
CRp:&#xD;
All CR criteria except for residual thrombocytopenia (platelet counts &lt; 100 x 10⁹/L)</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" lower_limit="22.7" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Response (DOR)</title>
        <description>Among participants who had a response of CR, CRi, CRp, PR, mCR, or MLFS based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion with an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Response (DOR)</title>
          <description>Among participants who had a response of CR, CRi, CRp, PR, mCR, or MLFS based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion with an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.9" upper_limit="18.5"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.9" upper_limit="5.1"/>
                    <measurement group_id="O3" value="NA" lower_limit="1.9" upper_limit="NA">Not estimable due to low number of events</measurement>
                    <measurement group_id="O4" value="12.0" lower_limit="0.4" upper_limit="NA">Not estimable due to low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Duration of Response</title>
        <description>For participants with an objective response based on the 2003 revised IWG criteria for AML assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. Participants without relapse, progressive disease or death were censored at the last response assessment date.&#xD;
Relapse (for participants who previously attained CR, Cri, CRp or MLFS): BM blasts ≥ 5%, reappearance of blasts in the blood or development of extramedullary disease.&#xD;
Disease progression (for participants who previously attained PR): development of new extramedullary disease, or&#xD;
For participants with 5% to 67% BM blasts at nadir:&#xD;
a &gt; 50% increase in BM blasts from nadir and that is ≥ 20%.&#xD;
For participants with ≥ 67% BM blasts at nadir:&#xD;
a doubling of the nadir absolute peripheral blood (PB) blast count and the final absolute PB blast count &gt; 10 x 10⁹/L.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
        <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Duration of Response</title>
          <description>For participants with an objective response based on the 2003 revised IWG criteria for AML assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. Participants without relapse, progressive disease or death were censored at the last response assessment date.&#xD;
Relapse (for participants who previously attained CR, Cri, CRp or MLFS): BM blasts ≥ 5%, reappearance of blasts in the blood or development of extramedullary disease.&#xD;
Disease progression (for participants who previously attained PR): development of new extramedullary disease, or&#xD;
For participants with 5% to 67% BM blasts at nadir:&#xD;
a &gt; 50% increase in BM blasts from nadir and that is ≥ 20%.&#xD;
For participants with ≥ 67% BM blasts at nadir:&#xD;
a doubling of the nadir absolute peripheral blood (PB) blast count and the final absolute PB blast count &gt; 10 x 10⁹/L.</description>
          <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.7" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Overall Survival</title>
        <description>Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
        <population>All participants in Phase 1 Dose Expansion who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Overall Survival</title>
          <description>Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.</description>
          <population>All participants in Phase 1 Dose Expansion who received at least one dose of study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="7.5" upper_limit="10.5"/>
                    <measurement group_id="O2" value="11.6" lower_limit="6.5" upper_limit="15.4"/>
                    <measurement group_id="O3" value="10.6" lower_limit="6.2" upper_limit="19.8"/>
                    <measurement group_id="O4" value="11.3" lower_limit="3.6" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Overall Survival</title>
        <description>Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Overall Survival</title>
          <description>Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.9" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Combined: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline</title>
        <description>Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 28 days before and 28 days after the first dose of treatment for Phase 1.&#xD;
Results are reported for all participants in Phase 1 combined and for the subset of participants with R/R AML.</description>
        <time_frame>Baseline to the end of treatment; overall median duration of treatment exposure in Phase 1 combined was 5.1 months (range 0.4, 34.2 months).</time_frame>
        <population>The population included all participants who received at least one dose of study treatment in Phase 1 Dose Escalation and Dose Expansion. Results were analyzed and are reported for Phase 1 combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Enasidenib - R/R AML</title>
            <description>Participants in Phase 1 Dose Escalation and Phase 1 Dose Expansion with R/R AML who received any dose of enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Enasidenib</title>
            <description>Participants in Phase 1 Dose Escalation and Phase 1 Dose Expansion who received any dose of enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Combined: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline</title>
          <description>Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 28 days before and 28 days after the first dose of treatment for Phase 1.&#xD;
Results are reported for all participants in Phase 1 combined and for the subset of participants with R/R AML.</description>
          <population>The population included all participants who received at least one dose of study treatment in Phase 1 Dose Escalation and Dose Expansion. Results were analyzed and are reported for Phase 1 combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Transfusion Dependent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Transfusion Independent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Combined: Percentage of Participants Who Achieved 56-Day Platelet Transfusion Independence Post-baseline</title>
        <description>Participants who achieved 56-day post-baseline platelet transfusion independence, i.e. with no platelet transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline platelet transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 28 days before and 28 days after the first dose of treatment for Phase 1.&#xD;
Results are reported for all participants in Phase 1 combined and for the subset of participants with R/R AML.</description>
        <time_frame>Baseline to the end of treatment; overall median duration of treatment exposure in Phase 1 combined was 5.1 months (range 0.4, 34.2 months).</time_frame>
        <population>The population included all participants who received at least one dose of study treatment in Phase 1 Dose Escalation and Dose Expansion. Results were analyzed and are reported for Phase 1 combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Enasidenib - R/R AML</title>
            <description>Participants in Phase 1 Dose Escalation and Phase 1 Dose Expansion with R/R AML who received any dose of enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Enasidenib</title>
            <description>Participants in Phase 1 Dose Escalation and Phase 1 Dose Expansion who received any dose of enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Combined: Percentage of Participants Who Achieved 56-Day Platelet Transfusion Independence Post-baseline</title>
          <description>Participants who achieved 56-day post-baseline platelet transfusion independence, i.e. with no platelet transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline platelet transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 28 days before and 28 days after the first dose of treatment for Phase 1.&#xD;
Results are reported for all participants in Phase 1 combined and for the subset of participants with R/R AML.</description>
          <population>The population included all participants who received at least one dose of study treatment in Phase 1 Dose Escalation and Dose Expansion. Results were analyzed and are reported for Phase 1 combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Transfusion Dependent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Transfusion Independent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline</title>
        <description>Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.</description>
        <time_frame>Baseline to the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline</title>
          <description>Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Transfusion Dependent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Transfusion Independent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Percentage of Participants Who Achieved 56-Day Platelet Transfusion Independence Post-baseline</title>
        <description>Participants who achieved 56-day post-baseline platelet transfusion independence, i.e. with no platelet transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline platelet transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.</description>
        <time_frame>Baseline to the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Percentage of Participants Who Achieved 56-Day Platelet Transfusion Independence Post-baseline</title>
          <description>Participants who achieved 56-day post-baseline platelet transfusion independence, i.e. with no platelet transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline platelet transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Transfusion Dependent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Transfusion Independent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival (EFS)</title>
        <description>Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurs first. Participants without an EFS event were censored at the date of the last adequate response assessment.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
        <population>All participants in Phase 1 Dose Expansion who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival (EFS)</title>
          <description>Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurs first. Participants without an EFS event were censored at the date of the last adequate response assessment.</description>
          <population>All participants in Phase 1 Dose Expansion who received at least one dose of study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.8" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.6" upper_limit="8.8"/>
                    <measurement group_id="O3" value="9.2" lower_limit="2.8" upper_limit="NA">Not estimable due to the low number of events</measurement>
                    <measurement group_id="O4" value="3.8" lower_limit="1.8" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival</title>
        <description>Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurred first. Participants without an EFS event were censored at the date of the last adequate response assessment.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
        <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival</title>
          <description>Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurred first. Participants without an EFS event were censored at the date of the last adequate response assessment.</description>
          <population>All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Complete Response (DOCR)</title>
        <description>Among participants who had a response of CR based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS assessed by the Investigator, duration of complete response was calculated from the date of the first occurrence of complete response to the date of documented disease relapse, progression or death, whichever occurred earlier. DOCR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion with a complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Complete Response (DOCR)</title>
          <description>Among participants who had a response of CR based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS assessed by the Investigator, duration of complete response was calculated from the date of the first occurrence of complete response to the date of documented disease relapse, progression or death, whichever occurred earlier. DOCR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion with a complete response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="1.9" upper_limit="NA">Not estimable due to low number of events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="3.7" upper_limit="NA">Not estimable due to low number of events</measurement>
                    <measurement group_id="O4" value="16.8" lower_limit="2.6" upper_limit="NA">Not estimable due to low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Duration of Complete Response</title>
        <description>Among participants who had a response of CR based on the 2003 revised IWG criteria for AML assessed by the Investigator, duration of complete response was calculated from the date of the first occurrence of complete response to the date of documented disease relapse, progression or death, whichever occurred earlier. DOCR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
        <time_frame>From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).</time_frame>
        <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had a complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Duration of Complete Response</title>
          <description>Among participants who had a response of CR based on the 2003 revised IWG criteria for AML assessed by the Investigator, duration of complete response was calculated from the date of the first occurrence of complete response to the date of documented disease relapse, progression or death, whichever occurred earlier. DOCR was estimated using the Kaplan-Meier method.&#xD;
Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.</description>
          <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had a complete response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="2.8" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation: Time to First Response by Total Daily Dose</title>
        <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, mCR (for MDS) or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS as assessed by the Investigator.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Escalation who had an objective response. Participants were grouped according to assigned total daily dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 60 mg</title>
            <description>Participants received enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg</title>
            <description>Participants received enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg</title>
            <description>Participants received enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg</title>
            <description>Participants received enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg</title>
            <description>Participants received enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg</title>
            <description>Participants received enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg</title>
            <description>Participants received enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg</title>
            <description>Participants received enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Time to First Response by Total Daily Dose</title>
          <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, mCR (for MDS) or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS as assessed by the Investigator.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Escalation who had an objective response. Participants were grouped according to assigned total daily dose.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.9" upper_limit="0.9"/>
                    <measurement group_id="O4" value="1.8" lower_limit="0.6" upper_limit="5.6"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.6" upper_limit="8.6"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0.5" upper_limit="5.7"/>
                    <measurement group_id="O7" value="2.1" lower_limit="1.0" upper_limit="3.7"/>
                    <measurement group_id="O8" value="2.8" lower_limit="0.5" upper_limit="3.8"/>
                    <measurement group_id="O9" value="1.9" lower_limit="0.5" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Time to First Response</title>
        <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, mCR (for MDS) or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS as assessed by the Investigator.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion who had an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Time to First Response</title>
          <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, mCR (for MDS) or MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS as assessed by the Investigator.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion who had an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.5" upper_limit="9.4"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.9" upper_limit="5.5"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.0" upper_limit="3.8"/>
                    <measurement group_id="O4" value="1.4" lower_limit="0.5" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Time to First Response</title>
        <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML as assessed by the Investigator.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Time to First Response</title>
          <description>Time to response is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML as assessed by the Investigator.</description>
          <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.9" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation: Time to Best Response by Total Daily Dose</title>
        <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Escalation and who had an objective response. Participants were grouped according to assigned total daily dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 60 mg</title>
            <description>Participants received enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg</title>
            <description>Participants received enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg</title>
            <description>Participants received enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg</title>
            <description>Participants received enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg</title>
            <description>Participants received enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg</title>
            <description>Participants received enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg</title>
            <description>Participants received enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg</title>
            <description>Participants received enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Time to Best Response by Total Daily Dose</title>
          <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Escalation and who had an objective response. Participants were grouped according to assigned total daily dose.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.8" upper_limit="5.6"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.9" upper_limit="0.9"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0.6" upper_limit="9.2"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.6" upper_limit="9.7"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0.5" upper_limit="5.7"/>
                    <measurement group_id="O7" value="3.8" lower_limit="2.1" upper_limit="7.5"/>
                    <measurement group_id="O8" value="3.7" lower_limit="0.5" upper_limit="3.8"/>
                    <measurement group_id="O9" value="1.9" lower_limit="0.5" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Time to Best Response</title>
        <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Part 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion who had an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Time to Best Response</title>
          <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion who had an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="0.9" upper_limit="11.2"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.9" upper_limit="5.5"/>
                    <measurement group_id="O3" value="3.7" lower_limit="1.8" upper_limit="12.9"/>
                    <measurement group_id="O4" value="4.6" lower_limit="0.6" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Time to Best Response</title>
        <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML per investigator assessment.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Time to Best Response</title>
          <description>Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML per investigator assessment.</description>
          <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="0.9" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation: Time to Complete Response by Total Daily Dose</title>
        <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the Phase 1 Dose Escalation phase was 5.0 months (range 0.4 to 34.2 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Escalation with a complete response. Participants were grouped according to assigned total daily dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation: Enasidenib 50 mg</title>
            <description>Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation: Enasidenib 60 mg</title>
            <description>Participants received enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation: Enasidenib 75 mg</title>
            <description>Participants received enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation: Enasidenib 100 mg</title>
            <description>Participants received enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation: Enasidenib 150 mg</title>
            <description>Participants received enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation: Enasidenib 200 mg</title>
            <description>Participants received enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation: Enasidenib 300 mg</title>
            <description>Participants received enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Phase 1 Dose Escalation: Enasidenib 450 mg</title>
            <description>Participants received enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Phase 1 Dose Escalation: Enasidenib 650 mg</title>
            <description>Participants received enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation: Time to Complete Response by Total Daily Dose</title>
          <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Escalation with a complete response. Participants were grouped according to assigned total daily dose.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.2" upper_limit="5.6"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.9" upper_limit="2.9"/>
                    <measurement group_id="O4" value="3.6" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O5" value="6.8" lower_limit="3.8" upper_limit="9.7"/>
                    <measurement group_id="O6" value="0.6" lower_limit="0.6" upper_limit="0.6"/>
                    <measurement group_id="O7" value="4.7" lower_limit="3.8" upper_limit="7.5"/>
                    <measurement group_id="O8" value="3.8" lower_limit="3.7" upper_limit="3.8"/>
                    <measurement group_id="O9" value="2.1" lower_limit="0.5" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Expansion: Time to Complete Response</title>
        <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Part 1 Dose Expansion was 5.2 months (range 0.5 to 32.8 months).</time_frame>
        <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion who had a complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
            <description>Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
            <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
            <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
            <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Expansion: Time to Complete Response</title>
          <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.</description>
          <population>Participants who received at least one dose of study treatment in Phase 1 Dose Expansion who had a complete response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="5.6" lower_limit="3.4" upper_limit="12.9"/>
                    <measurement group_id="O4" value="9.4" lower_limit="1.8" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Dose Expansion: Time to Complete Response</title>
        <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML per investigator assessment.</description>
        <time_frame>Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).</time_frame>
        <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had a complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants with relapsed or refractory (R/R) AML received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Dose Expansion: Time to Complete Response</title>
          <description>Time to complete response is defined as the time from the date of the first dose to the date of the first complete response based on the 2003 revised IWG criteria for AML per investigator assessment.</description>
          <population>Participants in Phase 2 with R/R AML who received at least one dose of study treatment and who had a complete response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="0.9" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Dose Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for assessment of enasidenib pharmacokinetics (PK).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Dose Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for assessment of enasidenib pharmacokinetics (PK).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3364" spread="59.7"/>
                    <measurement group_id="O2" value="3020" spread="58.4"/>
                    <measurement group_id="O3" value="5319" spread="57.0"/>
                    <measurement group_id="O4" value="6634" spread="79.6"/>
                    <measurement group_id="O5" value="9397" spread="32.1"/>
                    <measurement group_id="O6" value="11550" spread="49.2"/>
                    <measurement group_id="O7" value="15268" spread="42.0"/>
                    <measurement group_id="O8" value="15039" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="31580" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4120" spread="61.5"/>
                    <measurement group_id="O2" value="3925" spread="58.4"/>
                    <measurement group_id="O3" value="6834" spread="54.1"/>
                    <measurement group_id="O4" value="8616" spread="76.5"/>
                    <measurement group_id="O5" value="11819" spread="31.3"/>
                    <measurement group_id="O6" value="14818" spread="49.2"/>
                    <measurement group_id="O7" value="20727" spread="41.0"/>
                    <measurement group_id="O8" value="19961" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="38711" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8987" spread="72.1"/>
                    <measurement group_id="O2" value="9611" spread="59.6"/>
                    <measurement group_id="O3" value="17330" spread="50.6"/>
                    <measurement group_id="O4" value="21656" spread="55.6"/>
                    <measurement group_id="O5" value="28989" spread="29.6"/>
                    <measurement group_id="O6" value="37703" spread="48.3"/>
                    <measurement group_id="O7" value="58743" spread="41.5"/>
                    <measurement group_id="O8" value="60846" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 72 Hours Postdose (AUC0-72) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 72 hours post-dose (AUC0-72) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to 72 Hours Postdose (AUC0-72) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 72 hours post-dose (AUC0-72) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19192" spread="138.4"/>
                    <measurement group_id="O2" value="20598" spread="79.9"/>
                    <measurement group_id="O3" value="37737" spread="53.9"/>
                    <measurement group_id="O4" value="58670" spread="59.5"/>
                    <measurement group_id="O5" value="76820" spread="31.2"/>
                    <measurement group_id="O6" value="95217" spread="57.2"/>
                    <measurement group_id="O7" value="160083" spread="12.0"/>
                    <measurement group_id="O8" value="244130" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17575" spread="105.1"/>
                    <measurement group_id="O2" value="19975" spread="68.6"/>
                    <measurement group_id="O3" value="39345" spread="51.9"/>
                    <measurement group_id="O4" value="53018" spread="74.2"/>
                    <measurement group_id="O5" value="76820" spread="31.2"/>
                    <measurement group_id="O6" value="95959" spread="50.5"/>
                    <measurement group_id="O7" value="134094" spread="32.6"/>
                    <measurement group_id="O8" value="157042" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="38711" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Maximum Concentration of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Concentration of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="569" spread="45.6"/>
                    <measurement group_id="O2" value="545" spread="64.0"/>
                    <measurement group_id="O3" value="1084" spread="51.6"/>
                    <measurement group_id="O4" value="1279" spread="56.1"/>
                    <measurement group_id="O5" value="1624" spread="29.5"/>
                    <measurement group_id="O6" value="2082" spread="46.5"/>
                    <measurement group_id="O7" value="3358" spread="43.1"/>
                    <measurement group_id="O8" value="3031" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="4670" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time to Maximum Concentration (Tmax) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time to Maximum Concentration (Tmax) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="1.00" upper_limit="4.08"/>
                    <measurement group_id="O2" value="5.83" lower_limit="1.92" upper_limit="24.25"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.13" upper_limit="21.42"/>
                    <measurement group_id="O4" value="4.00" lower_limit="0.67" upper_limit="71.97"/>
                    <measurement group_id="O5" value="3.98" lower_limit="2.00" upper_limit="24.00"/>
                    <measurement group_id="O6" value="4.08" lower_limit="1.00" upper_limit="48.55"/>
                    <measurement group_id="O7" value="8.89" lower_limit="2.95" upper_limit="72.17"/>
                    <measurement group_id="O8" value="18.61" lower_limit="13.33" upper_limit="23.88"/>
                    <measurement group_id="O9" value="6.17" lower_limit="6.17" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Apparent Terminal Phase Half-life (t½) of Enasidenib After a Single Oral Dose on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
T1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Apparent Terminal Phase Half-life (t½) of Enasidenib After a Single Oral Dose on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
T1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="124.6"/>
                    <measurement group_id="O2" value="36.8" spread="57.3"/>
                    <measurement group_id="O3" value="52.6" spread="109.5"/>
                    <measurement group_id="O4" value="65.9" spread="86.5"/>
                    <measurement group_id="O5" value="96.2" spread="60.1"/>
                    <measurement group_id="O6" value="73.8" spread="18.8"/>
                    <measurement group_id="O7" value="91.3" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="102"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34338" spread="62.5"/>
                    <measurement group_id="O2" value="81775" spread="35.2"/>
                    <measurement group_id="O3" value="103364" spread="34.1"/>
                    <measurement group_id="O4" value="135649" spread="31.4"/>
                    <measurement group_id="O5" value="162308" spread="18.0"/>
                    <measurement group_id="O6" value="43407" spread="106.5"/>
                    <measurement group_id="O7" value="44360" spread="57.2"/>
                    <measurement group_id="O8" value="83444" spread="48.9"/>
                    <measurement group_id="O9" value="101462" spread="37.7"/>
                    <measurement group_id="O10" value="108404" spread="53.1"/>
                    <measurement group_id="O11" value="105098" spread="40.9"/>
                    <measurement group_id="O12" value="181186" spread="21.5"/>
                    <measurement group_id="O13" value="219708" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41108" spread="63.2"/>
                    <measurement group_id="O2" value="99954" spread="35.1"/>
                    <measurement group_id="O3" value="126765" spread="34.6"/>
                    <measurement group_id="O4" value="174409" spread="32.0"/>
                    <measurement group_id="O5" value="200661" spread="18.9"/>
                    <measurement group_id="O6" value="61226" spread="117.0"/>
                    <measurement group_id="O7" value="53067" spread="50.1"/>
                    <measurement group_id="O8" value="104824" spread="47.6"/>
                    <measurement group_id="O9" value="126237" spread="37.8"/>
                    <measurement group_id="O10" value="132718" spread="52.0"/>
                    <measurement group_id="O11" value="131523" spread="43.0"/>
                    <measurement group_id="O12" value="199749" spread="24.0"/>
                    <measurement group_id="O13" value="269750" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="107"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41108" spread="63.2"/>
                    <measurement group_id="O2" value="99954" spread="35.1"/>
                    <measurement group_id="O3" value="126765" spread="34.6"/>
                    <measurement group_id="O4" value="174409" spread="32.0"/>
                    <measurement group_id="O5" value="200661" spread="18.9"/>
                    <measurement group_id="O6" value="51273" spread="111.1"/>
                    <measurement group_id="O7" value="53067" spread="50.1"/>
                    <measurement group_id="O8" value="100119" spread="49.7"/>
                    <measurement group_id="O9" value="126237" spread="37.8"/>
                    <measurement group_id="O10" value="132718" spread="52.0"/>
                    <measurement group_id="O11" value="131523" spread="43.0"/>
                    <measurement group_id="O12" value="202702" spread="17.8"/>
                    <measurement group_id="O13" value="256155" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Maximum Concentration (Cmax) of Enasidenib After Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Concentration (Cmax) of Enasidenib After Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="107"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5300" spread="71.9"/>
                    <measurement group_id="O2" value="12538" spread="39.2"/>
                    <measurement group_id="O3" value="15860" spread="34.5"/>
                    <measurement group_id="O4" value="23962" spread="25.3"/>
                    <measurement group_id="O5" value="26715" spread="24.7"/>
                    <measurement group_id="O6" value="6543" spread="124.9"/>
                    <measurement group_id="O7" value="6922" spread="64.2"/>
                    <measurement group_id="O8" value="13012" spread="46.5"/>
                    <measurement group_id="O9" value="15734" spread="38.6"/>
                    <measurement group_id="O10" value="17990" spread="64.0"/>
                    <measurement group_id="O11" value="18505" spread="42.4"/>
                    <measurement group_id="O12" value="28049" spread="23.4"/>
                    <measurement group_id="O13" value="35269" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time to Maximum Concentration (Tmax) of Enasidenib After Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time to Maximum Concentration (Tmax) of Enasidenib After Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="107"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.00" upper_limit="3.92"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.50" upper_limit="9.83"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="4.47" lower_limit="0.48" upper_limit="9.83"/>
                    <measurement group_id="O5" value="1.54" lower_limit="1.00" upper_limit="9.83"/>
                    <measurement group_id="O6" value="3.02" lower_limit="0.00" upper_limit="10.00"/>
                    <measurement group_id="O7" value="4.04" lower_limit="1.00" upper_limit="10.08"/>
                    <measurement group_id="O8" value="1.02" lower_limit="0.00" upper_limit="10.00"/>
                    <measurement group_id="O9" value="2.13" lower_limit="0.70" upper_limit="9.83"/>
                    <measurement group_id="O10" value="1.02" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O11" value="5.98" lower_limit="0.00" upper_limit="9.95"/>
                    <measurement group_id="O12" value="4.08" lower_limit="0.97" upper_limit="6.00"/>
                    <measurement group_id="O13" value="2.00" lower_limit="1.95" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After Single and Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of enasidenib was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 8 Hours Postdose (AUC0-8) of Enasidenib After Single and Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of enasidenib was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8134" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86505" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC 0-24) of Enasidenib After Single and Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC 0-24) of Enasidenib After Single and Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27889" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263131" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After Single and Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Enasidenib After Single and Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17447" spread="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185566" spread="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Maximum Concentration (Cmax) of Enasidenib After Single and Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Maximum Concentration (Cmax) of Enasidenib After Single and Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13126" spread="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Time to Maximum Concentration (Tmax) of Enasidenib After Single and Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Time to Maximum Concentration (Tmax) of Enasidenib After Single and Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" lower_limit="1.83" upper_limit="27.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="0.00" upper_limit="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Apparent Terminal Phase Half-life (t1/2) of Enasidenib After Single and Multiple Oral Doses</title>
        <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1. t1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Apparent Terminal Phase Half-life (t1/2) of Enasidenib After Single and Multiple Oral Doses</title>
          <description>Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1. t1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to hour 8 post-dose (AUC 0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation and Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to hour 8 post-dose (AUC 0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation and Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="83.6"/>
                    <measurement group_id="O2" value="187" spread="134.4"/>
                    <measurement group_id="O3" value="276" spread="80.6"/>
                    <measurement group_id="O4" value="276" spread="104.1"/>
                    <measurement group_id="O5" value="558" spread="70.3"/>
                    <measurement group_id="O6" value="530" spread="91.1"/>
                    <measurement group_id="O7" value="526" spread="58.8"/>
                    <measurement group_id="O8" value="384" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="1470" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="80.4"/>
                    <measurement group_id="O2" value="258" spread="135.1"/>
                    <measurement group_id="O3" value="383" spread="72.3"/>
                    <measurement group_id="O4" value="379" spread="99.3"/>
                    <measurement group_id="O5" value="735" spread="65.1"/>
                    <measurement group_id="O6" value="716" spread="86.8"/>
                    <measurement group_id="O7" value="757" spread="57.5"/>
                    <measurement group_id="O8" value="548" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="1893" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474" spread="80.4"/>
                    <measurement group_id="O2" value="777" spread="111.7"/>
                    <measurement group_id="O3" value="1238" spread="54.4"/>
                    <measurement group_id="O4" value="1222" spread="71.4"/>
                    <measurement group_id="O5" value="2128" spread="54.2"/>
                    <measurement group_id="O6" value="2159" spread="75.4"/>
                    <measurement group_id="O7" value="2477" spread="51.5"/>
                    <measurement group_id="O8" value="2274" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 72 Hours Postdose (AUC0-72) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 72 hours post-dose (AUC0-72) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 72 Hours Postdose (AUC0-72) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 72 hours post-dose (AUC0-72) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1403" spread="93.7"/>
                    <measurement group_id="O2" value="2121" spread="104.8"/>
                    <measurement group_id="O3" value="3427" spread="40.9"/>
                    <measurement group_id="O4" value="4283" spread="58.0"/>
                    <measurement group_id="O5" value="7188" spread="43.6"/>
                    <measurement group_id="O6" value="7634" spread="66.2"/>
                    <measurement group_id="O7" value="10673" spread="29.8"/>
                    <measurement group_id="O8" value="17591" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1403" spread="93.7"/>
                    <measurement group_id="O2" value="2101" spread="86.2"/>
                    <measurement group_id="O3" value="3560" spread="40.0"/>
                    <measurement group_id="O4" value="3764" spread="83.8"/>
                    <measurement group_id="O5" value="7188" spread="43.6"/>
                    <measurement group_id="O6" value="7070" spread="62.0"/>
                    <measurement group_id="O7" value="6531" spread="93.9"/>
                    <measurement group_id="O8" value="8035" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="1893" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Maximum Concentration of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Concentration of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="89.3"/>
                    <measurement group_id="O2" value="47" spread="68.3"/>
                    <measurement group_id="O3" value="74" spread="52.3"/>
                    <measurement group_id="O4" value="79" spread="60.6"/>
                    <measurement group_id="O5" value="126" spread="39.4"/>
                    <measurement group_id="O6" value="138" spread="47.4"/>
                    <measurement group_id="O7" value="151" spread="52.4"/>
                    <measurement group_id="O8" value="188" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O9" value="242" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time to Maximum Concentration (Tmax) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time to Maximum Concentration (Tmax) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.38" lower_limit="3.00" upper_limit="70.42"/>
                    <measurement group_id="O2" value="10.00" lower_limit="1.92" upper_limit="69.50"/>
                    <measurement group_id="O3" value="10.00" lower_limit="3.00" upper_limit="71.00"/>
                    <measurement group_id="O4" value="48.00" lower_limit="3.00" upper_limit="74.42"/>
                    <measurement group_id="O5" value="24.12" lower_limit="6.20" upper_limit="72.10"/>
                    <measurement group_id="O6" value="47.33" lower_limit="1.98" upper_limit="72.82"/>
                    <measurement group_id="O7" value="48.10" lower_limit="7.95" upper_limit="72.17"/>
                    <measurement group_id="O8" value="59.88" lower_limit="48.25" upper_limit="71.50"/>
                    <measurement group_id="O9" value="6.17" lower_limit="6.17" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Apparent Terminal Phase Half-life (t½) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
t1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Apparent Terminal Phase Half-life (t½) of AGI-16903 After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
t1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PK parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O2" value="46.9" spread="125.7"/>
                    <measurement group_id="O3" value="29.0" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O4" value="69.2" spread="161.0"/>
                    <measurement group_id="O5" value="106.4" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="102"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4028" spread="82.9"/>
                    <measurement group_id="O2" value="7656" spread="47.5"/>
                    <measurement group_id="O3" value="7340" spread="59.8"/>
                    <measurement group_id="O4" value="10655" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O5" value="16638" spread="15.7"/>
                    <measurement group_id="O6" value="4395" spread="125.7"/>
                    <measurement group_id="O7" value="3281" spread="87.3"/>
                    <measurement group_id="O8" value="7645" spread="42.7"/>
                    <measurement group_id="O9" value="10720" spread="38.3"/>
                    <measurement group_id="O10" value="11579" spread="47.5"/>
                    <measurement group_id="O11" value="9961" spread="36.0"/>
                    <measurement group_id="O12" value="15888" spread="35.4"/>
                    <measurement group_id="O13" value="20480" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to 10 Hours Postdose (AUC0-10) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 10 hours post-dose (AUC0-10) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4830" spread="82.9"/>
                    <measurement group_id="O2" value="9437" spread="46.8"/>
                    <measurement group_id="O3" value="9002" spread="60.0"/>
                    <measurement group_id="O4" value="13463" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O5" value="20705" spread="16.1"/>
                    <measurement group_id="O6" value="6502" spread="132.7"/>
                    <measurement group_id="O7" value="3954" spread="80.6"/>
                    <measurement group_id="O8" value="9502" spread="42.0"/>
                    <measurement group_id="O9" value="13263" spread="40.1"/>
                    <measurement group_id="O10" value="14303" spread="47.2"/>
                    <measurement group_id="O11" value="12448" spread="35.0"/>
                    <measurement group_id="O12" value="17963" spread="18.7"/>
                    <measurement group_id="O13" value="22102" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="107"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4830" spread="82.9"/>
                    <measurement group_id="O2" value="9437" spread="46.8"/>
                    <measurement group_id="O3" value="9002" spread="60.0"/>
                    <measurement group_id="O4" value="13463" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O5" value="20705" spread="16.1"/>
                    <measurement group_id="O6" value="5181" spread="133.1"/>
                    <measurement group_id="O7" value="3954" spread="80.6"/>
                    <measurement group_id="O8" value="9193" spread="42.1"/>
                    <measurement group_id="O9" value="13263" spread="40.1"/>
                    <measurement group_id="O10" value="14303" spread="47.2"/>
                    <measurement group_id="O11" value="12448" spread="35.0"/>
                    <measurement group_id="O12" value="17846" spread="33.7"/>
                    <measurement group_id="O13" value="24187" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Maximum Concentration (Cmax) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Concentration (Cmax) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="107"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="619" spread="95.0"/>
                    <measurement group_id="O2" value="1149" spread="54.0"/>
                    <measurement group_id="O3" value="1096" spread="62.8"/>
                    <measurement group_id="O4" value="1717" spread="NA">Percent coefficient of variation could not be calculated due to small sample size</measurement>
                    <measurement group_id="O5" value="2651" spread="13.6"/>
                    <measurement group_id="O6" value="680" spread="148.1"/>
                    <measurement group_id="O7" value="518" spread="99.8"/>
                    <measurement group_id="O8" value="1199" spread="42.3"/>
                    <measurement group_id="O9" value="1640" spread="30.2"/>
                    <measurement group_id="O10" value="1817" spread="55.0"/>
                    <measurement group_id="O11" value="1687" spread="37.7"/>
                    <measurement group_id="O12" value="2415" spread="33.2"/>
                    <measurement group_id="O13" value="3135" spread="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time to Maximum Concentration (Tmax) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 2 Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time to Maximum Concentration (Tmax) of AGI-16903 After Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="107"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.00" upper_limit="4.17"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="0.52" lower_limit="0.33" upper_limit="7.97"/>
                    <measurement group_id="O4" value="1.48" lower_limit="1.00" upper_limit="1.97"/>
                    <measurement group_id="O5" value="1.54" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="2.92" lower_limit="0.00" upper_limit="3.92"/>
                    <measurement group_id="O7" value="1.58" lower_limit="1.00" upper_limit="6.08"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.00" upper_limit="10.00"/>
                    <measurement group_id="O9" value="4.00" lower_limit="2.00" upper_limit="9.83"/>
                    <measurement group_id="O10" value="1.00" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O11" value="5.98" lower_limit="0.00" upper_limit="9.95"/>
                    <measurement group_id="O12" value="2.98" lower_limit="0.97" upper_limit="6.00"/>
                    <measurement group_id="O13" value="1.97" lower_limit="1.95" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323" spread="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7409" spread="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1482" spread="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23963" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="829" spread="138.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16593" spread="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Maximum Concentration (Cmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Maximum Concentration (Cmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1158" spread="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="2.00" upper_limit="29.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="0.00" upper_limit="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Apparent Terminal Phase Half-life (t1/2) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
        <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1. T1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Enasidenib 100 mg QD</title>
            <description>Participants received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Apparent Terminal Phase Half-life (t1/2) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib</title>
          <description>AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters.&#xD;
Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1. T1/2 was not calculated when the terminal elimination rate constant (λz) was not estimable.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="116.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7506" spread="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84600" spread="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24631" spread="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263131" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Maximum Concentration (Cmax) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Maximum Concentration (Cmax) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1423" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13057" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Time to Maximum Concentration (Tmax) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Time to Maximum Concentration (Tmax) After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="0.67" upper_limit="71.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.00" upper_limit="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, and 8 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: AUC From Time Zero to 8 Hours Postdose (AUC0-8) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304" spread="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7555" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: AUC From Time Zero to 24 Hours Postdose (AUC0-24) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.&#xD;
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1352" spread="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23963" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Maximum Concentration (Cmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Maximum Concentration (Cmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1183" spread="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
        <time_frame>Day -3 (Phase 1 only) predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose or Cycle 1 Day 1 (Phase 2) and Cycle 2 Day 1 (Phase 1 &amp; 2) at predose and 2, 4, 6, 8, and 24 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 and 2: Enasidenib 100 mg QD</title>
            <description>Participants in Phase 1 and 2 who received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib 100 mg QD</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3) for single dose PK analysis, and underwent PK assessments on Cycle 2, Day 1 for multiple dose (steady-state) PK analysis. Participants in Phase 2 underwent PK assessments on Cycle 1, Day 1 for single dose analysis and on Cycle 2, Day 1 for multiple dose (steady-state) analysis.&#xD;
AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.</description>
          <population>Participants who received enasidenib on Day -3 or Cycle 1, Day 1 and Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took &lt; 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.&#xD;
Participants in Phase 1 and 2 who received enasidenib 100 mg QD are combined for the analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -3 / Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.44" lower_limit="2.00" upper_limit="74.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="0.00" upper_limit="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Percent Change From Baseline for Area Under the Effect Concentration Time Curve From Time 0 to 10 Hours Postdose (%BAUEC0-10) of 2-hydroxyglutarate (2-HG) on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of enasidenib; the LLOQ was 30.0 ng/mL.&#xD;
Area under the effect concentration time curve from time point zero (predose) up to 10 hours postdose (AUEC0-10) was calculated using the linear trapezoid rule. Percent change from Baseline for AUEC0-10 was calculated as (AUEC0-10 minus [Baseline*Tlast]) / (Baseline*Tlast) * 100, where Tlast corresponded to 10 hours and Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
        <time_frame>Screening visit, Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PD parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Percent Change From Baseline for Area Under the Effect Concentration Time Curve From Time 0 to 10 Hours Postdose (%BAUEC0-10) of 2-hydroxyglutarate (2-HG) on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of enasidenib; the LLOQ was 30.0 ng/mL.&#xD;
Area under the effect concentration time curve from time point zero (predose) up to 10 hours postdose (AUEC0-10) was calculated using the linear trapezoid rule. Percent change from Baseline for AUEC0-10 was calculated as (AUEC0-10 minus [Baseline*Tlast]) / (Baseline*Tlast) * 100, where Tlast corresponded to 10 hours and Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PD parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="1044.2"/>
                    <measurement group_id="O2" value="-13.55" spread="71.3"/>
                    <measurement group_id="O3" value="9.32" spread="862.2"/>
                    <measurement group_id="O4" value="-7.28" spread="270.8"/>
                    <measurement group_id="O5" value="-16.61" spread="127.7"/>
                    <measurement group_id="O6" value="-11.92" spread="95.3"/>
                    <measurement group_id="O7" value="-17.79" spread="92.0"/>
                    <measurement group_id="O8" value="-8.92" spread="NA">Could not be calculated when N = 1</measurement>
                    <measurement group_id="O9" value="-16.14" spread="NA">Could not be calculated when N = 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of enasidenib; the LLOQ was 30.0 ng/mL.&#xD;
Minimum percent change from Baseline response value post-dose over 10 hours was calculated as:&#xD;
(minimum observed concentration post-dose over 10 hours [Rmin] - Baseline) / Baseline * 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
        <time_frame>Screening visit, Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PD parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Dose Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of enasidenib; the LLOQ was 30.0 ng/mL.&#xD;
Minimum percent change from Baseline response value post-dose over 10 hours was calculated as:&#xD;
(minimum observed concentration post-dose over 10 hours [Rmin] - Baseline) / Baseline * 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PD parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Dose Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.9" spread="43.9"/>
                    <measurement group_id="O2" value="-37.7" spread="63.9"/>
                    <measurement group_id="O3" value="-38.6" spread="96.4"/>
                    <measurement group_id="O4" value="-47.5" spread="53.1"/>
                    <measurement group_id="O5" value="-59.6" spread="44.5"/>
                    <measurement group_id="O6" value="-56.9" spread="37.5"/>
                    <measurement group_id="O7" value="-74.7" spread="9.0"/>
                    <measurement group_id="O8" value="-31.5" spread="38.6"/>
                    <measurement group_id="O9" value="-36.9" spread="NA">Could not be calculated for N = 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time of Minimum Observed Concentration Over 72 Hours Postdose (Tmin) of 2-HG After a Single Oral Dose of Enasidenib on Day -3</title>
        <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.</description>
        <time_frame>Day -3 prior to the single dose of enasidenib and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, and 72 hours post-dose.</time_frame>
        <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PD parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg</title>
            <description>Participants received a single oral dose of enasidenib 30 mg on Day -3.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg</title>
            <description>Participants received a single oral dose of enasidenib 50 mg on Day -3.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg</title>
            <description>Participants received a single oral dose of enasidenib 75 mg on Day -3.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg</title>
            <description>Participants received a single oral dose of enasidenib 100 mg on Day -3.</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg</title>
            <description>Participants received a single oral dose of enasidenib 150 mg on Day -3.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 200 mg</title>
            <description>Participants received a single oral dose of enasidenib 200 mg on Day -3.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 300 mg</title>
            <description>Participants received a single oral dose of enasidenib 300 mg on Day -3.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 450 mg</title>
            <description>Participants received a single oral dose of enasidenib 450 mg on Day -3.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 650 mg</title>
            <description>Participants received a single oral dose of enasidenib 650 mg on Day -3.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time of Minimum Observed Concentration Over 72 Hours Postdose (Tmin) of 2-HG After a Single Oral Dose of Enasidenib on Day -3</title>
          <description>The first 3 participants enrolled in each cohort of the dose escalation phase and the first 15 participants enrolled in each arm of Phase 1 Expansion received a single dose of enasidenib three days prior to starting the 28-day dosing regimen (Day -3).&#xD;
Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.</description>
          <population>Participants who received 1 dose of enasidenib on Day -3 with sufficient data to determine PD parameters. Participants who received 2 doses on Day -3 or who received the incorrect dose were excluded.&#xD;
Participants in the Phase 1 Escalation BID and QD cohorts and Phase 1 Expansion cohorts were were grouped by dose for Day -3 analyses.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.78" lower_limit="24.00" upper_limit="72.38"/>
                    <measurement group_id="O2" value="8.00" lower_limit="1.13" upper_limit="72.42"/>
                    <measurement group_id="O3" value="23.92" lower_limit="2.92" upper_limit="71.42"/>
                    <measurement group_id="O4" value="48.00" lower_limit="0.50" upper_limit="73.58"/>
                    <measurement group_id="O5" value="48.20" lower_limit="1.00" upper_limit="72.30"/>
                    <measurement group_id="O6" value="48.70" lower_limit="6.07" upper_limit="72.45"/>
                    <measurement group_id="O7" value="48.10" lower_limit="24.42" upper_limit="72.17"/>
                    <measurement group_id="O8" value="30.79" lower_limit="13.33" upper_limit="48.25"/>
                    <measurement group_id="O9" value="8.17" lower_limit="8.17" upper_limit="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Percent Change From Baseline for Area Under the Effect Concentration Time Curve From Time 0 to 10 Hours Postdose of 2-HG After Multiple Oral Doses of Enasidenib</title>
        <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL. Area under the effect concentration time curve from time point zero (predose) up to 10 hours postdose (AUEC0-10) was calculated using the linear trapezoid rule. Percent change from baseline for AUEC0-10 was calculated as:&#xD;
(AUEC0-10 minus [Baseline*Tlast]) / (Baseline*Tlast) * 100, where Tlast corresponded to 10 hours and Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
        <time_frame>Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Percent Change From Baseline for Area Under the Effect Concentration Time Curve From Time 0 to 10 Hours Postdose of 2-HG After Multiple Oral Doses of Enasidenib</title>
          <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL. Area under the effect concentration time curve from time point zero (predose) up to 10 hours postdose (AUEC0-10) was calculated using the linear trapezoid rule. Percent change from baseline for AUEC0-10 was calculated as:&#xD;
(AUEC0-10 minus [Baseline*Tlast]) / (Baseline*Tlast) * 100, where Tlast corresponded to 10 hours and Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="89"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="77"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.18" spread="48.9"/>
                    <measurement group_id="O2" value="-62.60" spread="113.1"/>
                    <measurement group_id="O3" value="-87.19" spread="21.4"/>
                    <measurement group_id="O4" value="-84.24" spread="14.2"/>
                    <measurement group_id="O5" value="-79.40" spread="13.7"/>
                    <measurement group_id="O6" value="-58.76" spread="44.9"/>
                    <measurement group_id="O7" value="-69.00" spread="38.8"/>
                    <measurement group_id="O8" value="-64.23" spread="80.3"/>
                    <measurement group_id="O9" value="-71.67" spread="72.6"/>
                    <measurement group_id="O10" value="-79.34" spread="34.1"/>
                    <measurement group_id="O11" value="-87.74" spread="5.7"/>
                    <measurement group_id="O12" value="-62.89" spread="48.8"/>
                    <measurement group_id="O13" value="2.54" spread="NA">Could not be calculated for N = 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="89"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.01" spread="115.4"/>
                    <measurement group_id="O2" value="-35.49" spread="430.9"/>
                    <measurement group_id="O3" value="-64.63" spread="74.7"/>
                    <measurement group_id="O4" value="-83.93" spread="19.0"/>
                    <measurement group_id="O5" value="-78.07" spread="17.2"/>
                    <measurement group_id="O6" value="-81.51" spread="25.9"/>
                    <measurement group_id="O7" value="-66.41" spread="70.5"/>
                    <measurement group_id="O8" value="-53.46" spread="190.7"/>
                    <measurement group_id="O9" value="-37.70" spread="317.5"/>
                    <measurement group_id="O10" value="-27.70" spread="599.5"/>
                    <measurement group_id="O11" value="-87.88" spread="9.4"/>
                    <measurement group_id="O12" value="-76.98" spread="40.2"/>
                    <measurement group_id="O13" value="-82.28" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After Multiple Oral Doses of Enasidenib</title>
        <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.&#xD;
Minimum percent change from Baseline response value post-dose over 10 hours was calculated as:&#xD;
(minimum observed concentration post-dose over 10 hours [Rmin] - Baseline) / Baseline * 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
        <time_frame>Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After Multiple Oral Doses of Enasidenib</title>
          <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.&#xD;
Minimum percent change from Baseline response value post-dose over 10 hours was calculated as:&#xD;
(minimum observed concentration post-dose over 10 hours [Rmin] - Baseline) / Baseline * 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values.&#xD;
Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.</description>
          <population>Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="102"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="81"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.0" spread="42.0"/>
                    <measurement group_id="O2" value="-76.5" spread="56.4"/>
                    <measurement group_id="O3" value="-89.2" spread="18.9"/>
                    <measurement group_id="O4" value="-88.6" spread="12.3"/>
                    <measurement group_id="O5" value="-81.4" spread="11.6"/>
                    <measurement group_id="O6" value="-63.3" spread="40.7"/>
                    <measurement group_id="O7" value="-79.3" spread="22.0"/>
                    <measurement group_id="O8" value="-71.0" spread="57.1"/>
                    <measurement group_id="O9" value="-80.4" spread="45.7"/>
                    <measurement group_id="O10" value="-86.0" spread="25.3"/>
                    <measurement group_id="O11" value="-91.2" spread="4.0"/>
                    <measurement group_id="O12" value="-71.3" spread="31.5"/>
                    <measurement group_id="O13" value="-23.1" spread="NA">Could not be calculated for N = 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="102"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.8" spread="94.7"/>
                    <measurement group_id="O2" value="-54.5" spread="192.9"/>
                    <measurement group_id="O3" value="-68.9" spread="63.3"/>
                    <measurement group_id="O4" value="-89.5" spread="12.5"/>
                    <measurement group_id="O5" value="-80.7" spread="14.5"/>
                    <measurement group_id="O6" value="-84.8" spread="18.5"/>
                    <measurement group_id="O7" value="-70.6" spread="61.8"/>
                    <measurement group_id="O8" value="-65.6" spread="94.7"/>
                    <measurement group_id="O9" value="-47.2" spread="224.0"/>
                    <measurement group_id="O10" value="-35.6" spread="422.0"/>
                    <measurement group_id="O11" value="-89.8" spread="8.0"/>
                    <measurement group_id="O12" value="-60.6" spread="83.8"/>
                    <measurement group_id="O13" value="-53.5" spread="120.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time of Minimum Observed Concentration Over 10 Hours Postdose (Tmin) of 2-HG After Multiple Oral Doses of Enasidenib</title>
        <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.</description>
        <time_frame>Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.</time_frame>
        <population>Participants who received enasidenib on Cycle 1, Day 15 or Cycle 2, Day 1 with sufficient data to determine PD parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enasidenib 30 mg BID</title>
            <description>Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Enasidenib 50 mg BID</title>
            <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Enasidenib 75 mg BID</title>
            <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Enasidenib 100 mg BID</title>
            <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity</description>
          </group>
          <group group_id="O5">
            <title>Enasidenib 150 mg BID</title>
            <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Enasidenib 50 mg QD</title>
            <description>Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Enasidenib 75 mg QD</title>
            <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O8">
            <title>Enasidenib 100 mg QD</title>
            <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O9">
            <title>Enasidenib 150 mg QD</title>
            <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O10">
            <title>Enasidenib 200 mg QD</title>
            <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O11">
            <title>Enasidenib 300 mg QD</title>
            <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O12">
            <title>Enasidenib 450 mg QD</title>
            <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Enasidenib 650 mg QD</title>
            <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time of Minimum Observed Concentration Over 10 Hours Postdose (Tmin) of 2-HG After Multiple Oral Doses of Enasidenib</title>
          <description>Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.</description>
          <population>Participants who received enasidenib on Cycle 1, Day 15 or Cycle 2, Day 1 with sufficient data to determine PD parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis.&#xD;
Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="102"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="81"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.15" upper_limit="10.00"/>
                    <measurement group_id="O2" value="5.90" lower_limit="1.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="3.03" lower_limit="0.50" upper_limit="10.00"/>
                    <measurement group_id="O4" value="4.44" lower_limit="1.10" upper_limit="10.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="3.00" lower_limit="0.50" upper_limit="6.05"/>
                    <measurement group_id="O7" value="5.85" lower_limit="0.42" upper_limit="10.00"/>
                    <measurement group_id="O8" value="3.10" lower_limit="0.35" upper_limit="10.00"/>
                    <measurement group_id="O9" value="6.50" lower_limit="1.00" upper_limit="10.02"/>
                    <measurement group_id="O10" value="1.53" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O11" value="7.08" lower_limit="3.00" upper_limit="10.00"/>
                    <measurement group_id="O12" value="4.00" lower_limit="0.50" upper_limit="8.07"/>
                    <measurement group_id="O13" value="2.87" lower_limit="2.87" upper_limit="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="102"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.42" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="6.17" lower_limit="2.00" upper_limit="8.08"/>
                    <measurement group_id="O4" value="6.00" lower_limit="0.97" upper_limit="6.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="0.50" upper_limit="9.97"/>
                    <measurement group_id="O6" value="2.95" lower_limit="0.48" upper_limit="10.08"/>
                    <measurement group_id="O7" value="6.96" lower_limit="2.00" upper_limit="10.02"/>
                    <measurement group_id="O8" value="3.65" lower_limit="0.30" upper_limit="10.32"/>
                    <measurement group_id="O9" value="4.00" lower_limit="0.97" upper_limit="10.03"/>
                    <measurement group_id="O10" value="5.95" lower_limit="1.00" upper_limit="7.93"/>
                    <measurement group_id="O11" value="7.92" lower_limit="0.98" upper_limit="9.87"/>
                    <measurement group_id="O12" value="6.00" lower_limit="1.00" upper_limit="9.83"/>
                    <measurement group_id="O13" value="2.00" lower_limit="0.53" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of IP to 28 days after last dose; Median duration of treatment exposure was 5.0 months in Phase 1 Dose Escalation, 5.2 months in Phase 1 Dose Expansion, and 5.3 months in Phase 2. Safety follow-up is from 01 September 2017 to 29 July 2019, a maximum of 23 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 1 Dose Escalation: Enasidenib 30 mg BID</title>
          <description>Participants received enasidenib 30 mg tablets twice a day (BID) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Phase 1 Dose Escalation: Enasidenib 50 mg BID</title>
          <description>Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Phase 1 Dose Escalation: Enasidenib 75 mg BID</title>
          <description>Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E4">
          <title>Phase 1 Dose Escalation: Enasidenib 100 mg BID</title>
          <description>Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E5">
          <title>Phase 1 Dose Escalation: Enasidenib 150 mg BID</title>
          <description>Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E6">
          <title>Phase 1 Dose Escalation: Enasidenib 50 mg QD</title>
          <description>Participants received enasidenib 50 mg tablets once a day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E7">
          <title>Phase 1 Dose Escalation: Enasidenib 75 mg QD</title>
          <description>Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E8">
          <title>Phase 1 Dose Escalation: Enasidenib 100 mg QD</title>
          <description>Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E9">
          <title>Phase 1 Dose Escalation: Enasidenib 150 mg QD</title>
          <description>Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E10">
          <title>Phase 1 Dose Escalation: Enasidenib 200 mg QD</title>
          <description>Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E11">
          <title>Phase 1 Dose Escalation: Enasidenib 300 mg QD</title>
          <description>Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E12">
          <title>Phase 1 Dose Escalation: Enasidenib 450 mg QD</title>
          <description>Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E13">
          <title>Phase 1 Dose Escalation: Enasidenib 650 mg QD</title>
          <description>Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E14">
          <title>Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD</title>
          <description>Participants ≥ 60 years old with relapsed, refractory (R/R) AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E15">
          <title>Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD</title>
          <description>Participants &lt; 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E16">
          <title>Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD</title>
          <description>Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E17">
          <title>Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD</title>
          <description>Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E18">
          <title>Phase 2: Enasidenib 100 mg QD</title>
          <description>Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
        <group group_id="E19">
          <title>Safety Follow-Up: Enasidenib</title>
          <description>Participants remaining on treatment as of the 01 September 2017 data cut-off date continued to receive enasidenib on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="36" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="80" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="41" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="86" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BONE MARROW FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FEBRILE BONE MARROW APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="34" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HISTIOCYTOSIS HAEMATOPHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LEUKOSTASIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SPLEEN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SPLENIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>APPENDIX DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OEDEMA MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIODONTAL DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FACIAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MULTIPLE ORGAN DYSFUNCTION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SECRETION DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEPATOCELLULAR INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GRAFT VERSUS HOST DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABSCESS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANORECTAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ASPERGILLUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CELLULITIS OF MALE EXTERNAL GENITAL ORGAN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIARRHOEA INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GINGIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFECTIOUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPH GLAND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MICROCOCCUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PSOAS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUSITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUSITIS FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URETHRAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VIRAL MYOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIRENAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WOUND HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BILIRUBIN CONJUGATED INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD CULTURE POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD LACTIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MENSTRUATION NORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>IRON OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TUMOUR LYSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RHEUMATIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHLOROMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHOPROLIFERATIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FACIAL PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MANIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PENILE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SCROTAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PROMYELOCYTIC LEUKAEMIA DIFFERENTIATION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NASAL NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHILIC DERMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PYODERMA GANGRENOSUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGE PROPHYLAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INCISIONAL DRAINAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="49" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="106" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="40" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EOSINOPHILIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SPLENOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="24" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SYSTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GILBERT'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EAR CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EAR DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EXCESSIVE CERUMEN PRODUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOACUSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ADRENAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THYROID MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHALAZION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HYPERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EYE DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EYE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EYE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ABDOMINAL TENDERNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANAL INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANGINA BULLOSA HAEMORRHAGICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANOGENITAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>APHTHOUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHRONIC GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="27" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="42" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DUODENOGASTRIC REFLUX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FREQUENT BOWEL MOVEMENTS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIECTASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GINGIVAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GINGIVAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GLOSSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LIP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="21" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="58" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>POOR DENTAL CONDITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RETCHING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SALIVARY HYPERSECRETION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TONGUE COATED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="33" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AXILLARY PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CATHETER SITE EROSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="48" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFUSION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFUSION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUCOSAL DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NODULE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="33" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PRE-EXISTING CONDITION IMPROVED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="25" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TEMPERATURE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>XEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEPATOCELLULAR INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEPATOSPLENOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OCULAR ICTERUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GRAFT VERSUS HOST DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACTERIAL COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BONE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GENITAL INFECTION FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GINGIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHOID INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INCISION SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NAIL BED INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PULPITIS DENTAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUSITIS FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STENOTROPHOMONAS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VAGINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VIRAL RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANIMAL SCRATCH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EYE CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIORBITAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>STRESS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOOTH FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AMYLASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BILIRUBIN CONJUGATED INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="23" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN UNCONJUGATED INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD FIBRINOGEN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD IRON DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD URIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BRAIN NATRIURETIC PEPTIDE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BREATH SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARBON DIOXIDE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARDIAC MURMUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EPSTEIN-BARR VIRUS ANTIBODY POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HUMAN METAPNEUMOVIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>IMMUNOGLOBULINS DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MAMMOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL NECROSIS MARKER INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROTEIN TOTAL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN LEVEL DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINE OUTPUT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CELL DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="24" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="22" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERLIPASAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERNATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="28" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="20" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>IRON OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TUMOUR LYSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="18" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="18" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHONDROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>JOINT RANGE OF MOTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MOBILITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TENDON PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MELANOCYTIC NAEVUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VULVAL CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ESSENTIAL TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="26" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MYELITIS TRANSVERSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PAROSMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUS HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ADJUSTMENT DISORDER WITH DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANGER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="20" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LIBIDO DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>MOOD SWINGS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PSYCHOMOTOR RETARDATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOBACCO WITHDRAWAL SYMPTOMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLADDER SPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHROMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NOCTURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URETEROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URETHRITIS NONINFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GENITAL LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SCROTAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SCROTAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TESTICULAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VULVAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PROMYELOCYTIC LEUKAEMIA DIFFERENTIATION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="34" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="36" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="21" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PLAQUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PARANASAL SINUS HYPERSECRETION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PULMONARY GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RALES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RHONCHI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SINUS PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SNEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>UPPER-AIRWAY COUGH SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>BLOOD BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CAPILLARITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COLD SWEAT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DERMATITIS EXFOLIATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERTRICHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NAIL RIDGING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PAPULE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PHOTOSENSITIVITY REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SOLAR LENTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>TOXIC SKIN ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>TOOTH EXTRACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>LYMPHOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PALLOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results from a center cannot be submitted for publication before results of multicenter study are published unless it is &gt; 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne McClain, Senior Manager</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>908-673-9100</phone>
      <email>ClinicalTrialDisclosure@Celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

